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ROLE OF NEWLY SYNTHESIZED STEROID HORMONE ANTAGONISTS 
IN ADRENOCORTICOSTEROID HORMONE-INDUCED HYPERTENSION 
ABSTRACT 
A dissertation in partial fulfillment of the requirements for 
the degree of Doctor of Philosophy at the Virginia Commonwealth University 
Justicia Opoku-Edusei, Ph.D. 
Medical College of Virginia--Virginia Commonwealth University, 1990 
Major Director: Mohammed Y. Kalimi, Ph.D. 
Excess adrenocorticosteroid hormones such as glucocorticoids and 
mineralocorticoids is well known to induce hypertension in several animal species 
as well as in humans. Therefore, the development of potent and specific 
glucocorticoid and mineralocorticoid antagonists with antihypertensive effects is 
clinically necessary. steroid hormone antagonists being used therapeutically 
present serious endocrinology side effects such as the widely used 
antimineralocorticoid, spironolactone. The antiglucocorticoids available so far 
have been active only ill vitro or only weakly ill vivo. Recently, three new exciting 
adrenocorticosteroid hormone antagonists have been synthesized. RU 486 is a 
potent antiglucocorticoid (and antiprogesterone with potential as an abortifacient), 
RU 26752 and mespirenone, are novel mineralocorticoid antagonists. I studied 
x 
the antihypertensive effect of RU 486 , RU 26752 and mespirenone in Sprague­
Dawley rats with dexamethasone- or aldosterone-induced hypertension. In 
addition, the effect of these antagonists on the hypertension developed by genetic 
model, spontaneously hypertensive rats (SHR) were also studied. The SHR is the 
closest animal model to human essential hypertension and it is believed that 
adrenocorticosteroid hormones are involved in the induction and maintenance of 
the hypertension. The results obtained from my studies showed that RU 486 
administered simultaneously with dexamethasone prevented the hypertension 
induced by dexamethasone treatment. However, RU 486 had no effect on 
mineralocorticoid-induced hypertension. The administration of the 
antimineralocorticoid RU 26752 or mespirenone in combination with aldosterone 
successfully presented aldosterone-induced hypertension but not dexamethasone­
induced hypertension. Surprisingly, RU 486 caused a significant increase in the 
blood pressure of the SHR whilst mespirenone caused a slight decrease in blood 
pressure as compared to control SHR. 
The effect of these anti hormones on body/organ weights, fluid intake and 
urinary output was observed. Morphologically examination of the heart and 
kidney showed no abnormalities with treatment. These results suggest that 1) RU 
486 is specific in preventing dexamethasone-induced hypertension; 2) RU 26752 
and mespirenone are successful in preventing aldosterone-induced hypertension 
and 3) mineralocorticoids may be involved in the development and maintenance 
of hypertension in the SHR. 
INTRODUCfION 
The adrenal cortex has long been known to be involved in the pathogenesis 
of hypertension. It has been observed that hypertension cannot be produced or 
sustained without the adrenal cortex as bilateral adrenalectomy without steroid 
hormonal replacement leads to decreased blood pressure which causes circulatory 
collapse and eventuaIJy death (1 , 14). On the other hand, it is known that 
adrenocortical hyper-reactivity leads to an increase in the blood pressure (2,3). 
Several clinical and experimental studies indicate that adrenal steroids play an 
important role in the development and/or maintenance of various types of 
hypertension (4). Steroid hormones produced by the adrenal cortex are broadly 
classified into two categories, namely, glucocorticoids and mineralocorticoids. The 
exogenous administration of high amounts of glucocorticoid agonists such as 
dexamethasone (5-7) and mineralocorticoid agonist such as aldosterone (8-10) 
induce hypertension in several animal species as weIJ as in humans. In addition, 
adrenal hyperactivity is associated directly with hypertension in three disorders in 
humans: 1) Cushing's Syndrome, 2) Primary aldosteronism, 3) adrenocortical 
enzymatic defects. 
Cushing's Syndrome is due to the prolonged exposure to excessive levels of 
cortisol, the principal glucocorticoid of the human adrenal cortex. This disease 
1 
2 
can arise from endogenous glucocorticoid excess associated with tumors of the 
adrenal gland or the pituitary gland. The long-term exogenous administration of 
synthetic glucocorticoids used clinically to suppress inflammation and immunity in 
the treatment of diseases such as vasculitis, arthritis, skin diseases, malignancy, 
primary nephrotic syndrome, secondary glomerulonephritis and transplantation can 
also lead to Cushing's Syndrome (1 1). Since the introduction of synthetic 
adrenocortical steroids as therapy for these various diseases, hypertension has 
become the most frequent complication of long-term exposure to steroid therapy 
( 12-14). Whatever the anatomic cause or the source, high blood pressure is the 
rule in these patients. However, in Cushing's Syndrome patients there is a higher 
incidence of hypertension with the endogenous occurring disease (80%) than the 
long-term exogenous synthetic glucocorticoid administration (20%) (15, 16). The 
explanation for this observation may be due to the low or absent mineralocorticoid 
activity of synthetic glucocorticoids. Cushing's Syndrome is the cause of 
hypertension in one out of 300 hypertensives ( 1 1) .  This is a very aggressive 
disease with a 50% 5-year mortality rate if untreated ( 17). Even with present 
therapy, the mortality rate is still four times that of the general population ( 18). 
Thus, a new and more effective therapy is needed in the treatment of Cushing's 
Syndrome. 
The second disorder, primary aldosteronism, is due to the excessive 
production of aldosterone independent of the renin-angiotensin system, the main 
regulator of aldosterone production. Primary aldosteronism is the most common 
form of endocrine hypertension occurring in patients, mostly women, between the 
ages of 30 and 50 years. The syndrome of primary aldosteronism has been 
classified in four types: 
1. Aldosterone producing adenoma (APA) 
2. Adrenocorticol hyperplasia 
-idiopathatic hyperaldosteronism (IHA) 
-dexamethasone suppressible hyper-aldosteronism (DSH) 
-primary adrenal hyperplasia (P AH) 
3. Adrenocortical carcinoma 
4. Ectopic aldosterone-producing tumors 
The most common type of primary aldosteronism is unilateral aldosterone 
producing adenoma (APA) or Conn's Syndrome which accounts for 65% of 
primary aldosteronism (1) .  APA is characterized by increased aldosterone 
production from a unilateral adenoma and rarely is it bilateral. There is 
suppression of the renin-angiotensin system (RAS) and urinary potassium wasting 
which results in hypokalemia. AP A is the second most common cause of curable 
hypertension achieved through the surgical removal of the adrenal. On the other 
hand, the hypertension in the other three types of primary aldosteronism are not 
cured by adrenalectomy. The most common subtype of bilateral adrenocortical 
hyperplasia, idiopathic hyperaldosteronism (IHA) which accounts for 34% of the 
cases ( 19), unlike APA, the lHA occurs mostly as bilateral hyperplasia. The 
hypertension in 85% of these patients fails to improve with adrenalectomy which 
recurs within 1 to 2 weeks after surgery (19,20). Recognizing the type of primary 
aldosteronism is critical in the treatment of these patients as some can be cured 
partially or completely from hypertension by adrenalectomy while others cannot. 
3 
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Therefore, other non-surgical therapeutic measures such as the use of aldosterone 
antagonists like spironolactone are employed. 
Adrenocortical enzymatic disorder or congenital adrenal hyperplasia (CAH) 
syndrome is inherited in an autosomal recessive fashion and is characterized by 
three separate enzymatic defects in cortisol biosynthesis. The deficient enzymes in 
CAH, their frequency and the induction of hypertension are as follows: 
Adrenocortical Enzymatic Disorders 
Induction of 
Enzyme Deficiency Frequency Hypertension 
21 hydroxylase 90% No 
11S hydroxylase 8% Yes 
17 a hydroxylase 1% Yes 
The 1 1S hydroxylase and 17a hydroxylase deficiency lead to hypertension. 
The 1 1S-hydroxylation deficiency is characterized by accumulation of steroids 
proximal to the block such as 1 1-deoxycorticosterone (DOC) and a reduction in 
1 1-hydroxylated steroids such as cortisol, distal to the defect. 17-hydroxylase 
deficiency also increases the level of steroids proximal to the block and reduce 
production of cortisol distally, resulting in increased secretion of ACTH. High 
levels of ACTH induces the excess production of intermediate steroids including 
the mineralocorticoids, DOC, 18-hydroxyl DOC and 19-nor-DOC which contribute 
to the development of hypertension (1) .  
Adrenocortical steroids have been implicated in several models of 
experimental hypertension (21) and also in human essential hypertension, 
5 
particularly, in low renin essential hypertension ( 19). Essential hypertension 
simply means the cause(s) of the hypertension is unknown. It has been 
hypothesized that in essential hypertension excess production of adrenocortical 
steroids cause volume expansion (thus, suppression of renin production) which 
may contribute to the development of hypertension (22) . However, several studies 
have shown increased (23,24) or decreased blood volume (25) in essential 
hypertensive subjects. Some of these patients exhibit antihypertensive response to 
adrenal inhibitors (26-28), mineralocorticoid antagonists (22,29) and 
adrenalectomy (30). The potent mineralocorticoid 19-nor-DOC has been detected 
in high amounts in the urine of some patients with essential hypertension (31,32). 
Furthermore, other studies have shown increased adrenal activity in several 
models of hypertension (33,35). However, direct adrenocortical involvement 
remains to be proven. Thus, to investigate the causes and mechanisms involved in 
the pathogenesis of human hypertension, different experimental models are 
studied. There are several models of experimental hypertension: 
1 .  Mechanically-induced hypertension such as renovascular 
hypertension. 
2. Genetic models of experimental hypertension. 
3. Surgical manipulations such as adrenal regeneration hypertension. 
4. Chemically induced hypertension such as steroid-induced 
hypertension which is the focus of this work. 
1 . Renovascular Hypertension 
Goldblatt and his associates showed in 1934 that constriction of the renal 
artery in dogs produced and sustained hypertension (36). Therefore, this model of 
6 
experimental hypertension is also known as Goldblatt hypertension. Since then it 
has been shown in rats, sheep and rabbits (37,38,39). In this model, the renin­
angiotensin system (RAS) has been known to play a major role in regulating the 
blood pressure (40,41). Renin, produced by cells in the juxtaglomerular apparatus 
in the kidney (due to decreased pressure in renal artery) converts angiotensinogen 
produced by the liver to angiotensin I. Angiotensin I is converted to angiotensin 
II by angiotensin converting enzyme (ACE) which is produced in the lungs. Ang 
II is not only a potent vasoconstricting agent but also stimulates aldosterone 
production from the adrenal cortex. There are two different models of Goldblatt 
hypertension. The first model is known as the two kidney-one clip (2KlC) which 
involves constricting the renal artery while the contralateral kidney is intact. The 
second model, is the one kidney-one clip ( lK1C) in which one kidney is clipped 
and the contralateral kidney is removed. The mechanisms involved in increasing 
the blood pressure are different in these two models. The renin-angiotensin 
system (RAS) is believed to be responsible for the development of hypertension in 
the 2K1C model and not in the 1K1C model. This conclusion is based on the 
observation that plasma renin activity (PRA) is elevated during the pathogenesis 
of 2K1C hypertension (37,42,43). In addition, blocking the RAS with either All 
antagonists or ACE inhibitors reverse increased blood pressure in 2K1C animals 
(43-45). However, sodium balance in 2K1C animals has been reported to be 
normal (42,46), decreased (47) or transiently increased (48,49). Unlike the 2K1C 
model, the 1K1C model is not dependent on the RAS. Ang II antagonists and 
ACE inhibitors have no effect or are less effective in reversing 1KIC hypertension 
(43,44,50,51) and studies show a positive sodium balance. On the other hand, it 
has been suggested that the different mechanisms reported for the 2KlC and 
lKlC models may be due to the fact that several studies fail to consider the 
circadian rhythm for renin and aldosterone secretion, the severity of the renal 
artery constriction and species differences (21) . 
7 
The role of the adrenal cortex in renovascular hypertension has been 
investigated. It has been reported that bilateral adrenalectomy reduces renal 
hypertension unless there is hormone therapy (52) or saline is given (53). In 
contrast, adrenalectomy lowered the BP of renal hypertensive rat to normal levels 
even when they were maintained on saline (54). The administration of 
prednisolone, a glucocorticoid agonist, restored the blood pressure to hypertensive 
levels in adrenalectomized rats with renovascular hypertension (59). However, 
glucocorticoid replacement failed to increase pressure in adrenalectomized dog 
with renovascular hypertension (56). In adrenalectomized sheep given 
glucocorticoid and mineralocorticoid, lKlC hypertension persisted for two days 
after withdrawal of steroid (57) suggesting that the adrenal might not be that 
essential in renal hypertension. Another study showed that lKlC 
adrenalectomized dogs maintained on basal cortisone and l l-deoxycorticosterone 
(DOC) still developed hypertension (58). Since hypersecretion of these 
adrenocortical steroid hormones was not possible, it was concluded that the role of 
the adrenal was not essential for the development of lKlC hypertension. De 
Jong and his colleagues (59) compared renin-induced and 2KlC hypertension in 
intact and adrenalectomized rat given saline. They reported that renal 
hypertension developed in both intact and adrenalectomized 2KlC models. 
Renin-induced hypertension developed in intact rats but not in adrenalectomized 
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rats. However, high doses of renin were able to produce hypertension in 
adrenalectomized rats without steroid replacement. They concluded from these 
results that the adrenal is not essential for renin or renal hypertension (59). 
Watkins and associates (58) also reached a similar conclusion using 1K1C 
hypertensive dogs. On the other hand, a more significant role of the adrenal 
gland has been suggested by Ribeiro and Krakoff (60) and other researchers (61-
63). Before the infusion of saralasin, the blood pressure of 1K1C rats and 
adrenalectomized 1K1C was 174 mmHg and 142 mmHg, respectively, a difference 
of 32 mm. This difference became 68 mmHg after saralasin infusion due to a 
decrease in BP of the adrenalectomized 1K1C rats to 126 mmHg (but not in the 
intact 1K1C). Since no decrease in the BP was observed in the intact 1K1C rats 
with saralasin infusion, they contributed to the reduction in BP in the 
adrenalectomized rats to the lack of adrenals. Aldosterone level is increased 
throughout the development of 2K1C hypertension and only in the early stages of 
1K1C hypertension (21). The involvement of glucocorticoids in the pathogenesis 
of renovascular hypertension is sketchy but so far studies show increased levels 
(64) while others observed no change (65). Thus, all these studies seem to suggest 
that the adrenal gland serves a prominent but secondary role in the pathogenesis 
of renovascular hypertension. 
2. Genetic Forms of Experimental Hypertension 
Experimentally, there are different types of the genetic model. 
Dahl and Rapp Salt-Sensitive Rats 
Dahl and co-workers selectively bred Sprague-Dawley rats based on their 
blood pressure response to high salt intake (66) . Two strains were developed, 
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namely, susceptible (S) and resistant (R). The S rats developed hypertension 
rapidly on a high salt diet whereas the resistant rats did not. Rapp and Dahl have 
suggested the difference between S and R rats is due to a gene or genes 
controlling adrenocorticosteroids biosynthesis (67). Rapp and Dahl (68) used Fl 
and F2 generations of S x R cross to show that the relative activity of steroid 18-
hydroxylase and 1 1-B hydroxylase (which catalyses 18- and 19-hydroxylation of 
DOC) was being controlled by a single Mendelian gene with two alleles inherited 
in a codominant fashion. The involvement of these steroids have been 
investigated. It has been shown that R rats became hypertensive when connected 
to S rats on a high-salt diet (69). Blood taken from S rats reduced the excretion 
of sodium of isolated kidney from normotensive Sprague-Dawley rats (70). 
Adrenalectomy prevents the development of hypertension in S rats (71). The 
adrenal cortex in S rats show increased secretion in mineralocorticoids such as 18-
hydroxy-DOC (72), 19-nor-DOC (73,74). Also, Gomez-Sanchez reported high 
levels of corticosterone in the urine of S rats than R rats (73). This finding 
contradicts the observation of Rapp and Dahl (67) that blood levels of 
corticosterone and the in vitro biosynthesis is lower in S rats than R rats. These 
contradictory results have been explained by the difference in the level of 1 1-B 
hydroxysteroid dehydrogenase, the enzyme that catalyses the metabolism of 
corticosterone to l l-dehydrocorticosterone (75). The level of this enzyme has 
been found to be higher in the S rats than the R rats. 
Aside from increased mineralocorticoid secretion causing hypertension in 
the S rats, sex and age also play a role. The development of hypertension in 
female S rats with high salt intake is slower (67) which is contrary to reports that 
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female rats have higher 18-hydroxy-DOC and 19-nor-DOC than males (73). 
Therefore, the degree of response to salt by the S strain depends on factors such 
as age, sex, duration and the amount of dietary salt intake (H). 
Okamoto/Aoki Spontaneously Hypertensive Rats (SHR) 
This is a strain of rats which develop hypertension spontaneously as they 
grow. Okamoto and Aoki reported on this strain in 1963 (76). The most 
interesting aspect of this strain is the possibility that SHR may be the animal 
model for essential hypertension in humans. Extensive studies by Aoki (77) 
proved how critical the adrenals are in the development of hypertension in the 
SHR. When young prehypertensive SHR rats (less than 8 weeks old) are 
adrenalectomized, thyroidectomized or hypophysectomized, the development of 
hypertension is prevented (77). Even bilateral adrenalectomy in SHR with 
established hypertension normalized the blood pressure, however, unilateral 
adrenalectomy failed to reduce the hypertension. This is consistent in human 
studies where adrenalectomy reduces blood pressure and patients with untreated 
Addison's diseases have hypotension (21). Aoki and colleagues observed that the 
adrenocortical zones were hypertrophied in the SHR (78). Thus, the adrenal 
gland is critical in the hypertension of the SHR. 
However, other researchers do not agree totally with a critical role for the 
adrenal cortex in the development of hypertension in the SHR (79). Though 
adrenalectomy reduces the blood pressure rise, eventually hypertension was 
developed in the SHR due to the possible regeneration of accessory 
adrenocortical tissue (79,80). The role played by adrenocortical steroids have also 
been studied and the results are inconsistent. Several studies have shown the 
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involvement of glucocorticoids. Adrenalectomized prehypertensive SHR rats with 
glucocorticoid replacement restored hypertension while others have shown 
aldosterone replacement to be more important (for review see 81). 
Corticosterone levels at the time of significant blood pressure increase have been 
observed to be higher in the SHR than control rats (82), lower in the SHR (83), 
or unchanged (84). Recently, Hashimoto et al. (85) demonstrated the importance 
of the pituitary-adrenal axis indicating a more important role for glucocorticoid 
involvement. There has been a report of increased plasma aldosterone levels in 
SHR neonates (86). In addition, high levels of the potent mineralocorticoid 19-
nor-DOC is found in the urine of SHR rats (87). The variability in the results of 
adrenocortical function in hypertension in the SHR may be due to differences in 
numerous factors. These factors are 1) age of the SHR rat at the time of study 
since they develop hypertension after 8 weeks of age. Thus, it should be clear 
whether prehypertensive or hypertensive rats are being studied; 2) sex of the rat­
normally male SHR is used in these experiments so as to eliminate the effects of 
other hormones during menstruation or pregnancy; 3) high salt or low salt diet; 4) 
stress level when blood samples were taken for steroid measurements; 5) time of 
day blood samples were taken as the secretion of these steroids follow a circadian 
pattern; 6) strain of rats used in the experiment as controls for the SHR-whether 
Sprague-Dawley, Wistar!Kyoto, and so on; 7) source of the SHR as there may be 
differences in breeding in the various laboratories. 
The New Zealand Genetically Hypertensive (GH) Strain of Rat 
The New Zealand GH rat was developed by Smirk and Hall in 1958 (88) . 
These rats have significant increase in their blood pressure when they are only two 
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days old which progresses as they grow. Studies of adrenocortical function in 
these rats have focused on the renin-angiotensin-aldosterone system. However, 
the involvement of this system has been proved otherwise. The plasma renin 
activity (89) and plasma aldosterone level (90) is lower in GH rats than in control 
rats. In fact, inhibition of the renin-angiotensin system does not have any effect 
on the blood pressure of GH rats (91). Thus, the contention is that the renin­
angiotensin-aldosterone system is not involved in the pathogenesis of hypertension 
in GH rats though other mineralocorticoids other than aldosterone could play a 
role. Unfortunately, there has been no reports on other mineralocorticoids or 
glucocorticoids effect on this model. 
The Lyon Rat Strains 
Three strains of rats which are either hypertensive (LH) , normotensive 
(LN) or have low blood pressure (LL) have been developed by Vincent and co­
workers (92). This was achieved by inbreeding of Sprague-Dawley rats identified 
to have the highest, average or lowest blood pressures. Interestingly, the 
hypertension that eventually develops is much less than in the SHR. Gomez­
Sanchez et al. (93) have studied the role of adrenocortical steroids in the blood 
pressure level in the three strains. In prehypertensive rats, which is before the age 
of eight weeks, DOC levels increased significantly in the LH rats and decreased in 
LL rats compared with LH rats. Hence, DOC excretion was increased in the LH 
group accompanied with decreased corticosterone excretion. This observation 
suggests an abnormality in the adrenal cortex such as l IB-hydroxylase deficiency. 
The Milan Hypertensive Strain (MHS) of Rat 
MHS comes from the Wistar strain that were selectively bred from rats 
with systolic blood pressures over 160 mmHg (94). Studies of adrenocortical 
function in MH rats show a decreased plasma renin activity in prehypertensive 
rats which is surprisingly followed by normal and not decreased level of 
aldosterone (95,96). 
The Sabra Strains of Hypertension - Prone and Hypertension-Resistant Rats 
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These strains were selectively bred from the Hebrew University Sabro (SB) 
rats which had been uninephrectomized and saline-loaded with a blood pressure 
response to DOCA treatment. This resulted in the development of two strains. 
SBH that was hypertension-prone and SBN that was hypertension-resistant (97). 
The abnormal function of the pituitary-adrenal axis may be involved in this form 
of experimental hypertension as SBH rats have higher basal corticosterone levels 
which correlates with higher ACTH levels than in the SBN rats (64). 
3. Exnerimental Hypertension Through Surgery - Adrenal Regeneration 
Hypertension (ARH) 
It was demonstrated by Skelton that uninephrectomized adrenal-enucleated 
rats maintained on 1 % saline developed hypertension (98). An intact adrenal 
gland or corticosterone administration prevented ARH but an intact pituitary 
gland was necessary for the development of hypertension (99). Plasma levels of 
ACTH are increased after adrenal enucleation (100, 101). The regenerating 
adrenal gland may be secreting abnormal hormone or secreting an imbalance of 
normal hormone resulting in hypertension. In fact, it has been shown that 
regenerating adrenals secrete less corticosterone in response to stress ( 102) or to 
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ACTH ( 103). Not only do these glands secrete lower levels of corticosterone but 
also aldosterone (103-105). Further investigation into steroid synthesis of the 
regenerating adrenal cortex revealed a reduced ability to convert progesterone to 
corticosterone resulting in the accumulation of DOC which induces hypertension 
( 106). This observation suggests an impairment in l IB-hydroxylase enzyme in rats 
with ARH. 
In contrast, other investigators have reported increased levels of 18-
hydroxy-DOC and not DOC (107-109) whilst Rapp found a decrease in the levels 
of both corticosterone and 18-hydroxy-DOC (1 10). The inconsistency in results is 
due to the difference in age of rats after adrenal regeneration and in experimental 
protocol. High levels of the potent mineralocorticoid 19-nor DOC has been 
detected in the urine of rats with ARH (11 1). 
4. Experimental Hypertension Through Chemical Intervention - Steroid­
Induced Hypertension 
Adrenocortical steroid hormones as discussed previously play a very 
important role in blood pressure control. Adrenocortical hormones are broadly 
classified into two major categories, namely, glucocorticoids and 
mineralocorticoids. Steroid hormones known as glucocorticoids tend to be 
ubiquitous affecting inflammation, immunity and intermediate metabolism. 
Mineralocorticoids are vital in electrolyte balance. 
Mechanism of Action of Steroid Hormones 
Steroid hormones exert their biological effects by passing through the 
plasma membrane and binding to specific intracellular receptors in the target 
tissues. When hormone binds to the receptor, the receptor gets activated and the 
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hormone-receptor complex gets translocated into the nucleus. In the nucleus, the 
occupied receptor binds to specific DNA sequences which results in the regulation 
of transcription of those genes in the target tissues. Steroid hormones may cause 
the induction or the repression of gene transcription (1 12). If induction of 
transcription occurs, mRNA produced is translated to proteins in the cytoplasm 
resulting in de novo synthesis of proteins (translation) . Steroid hormones may also 
have non-genomic actions as some effects of these steroids are too fast with short 
duration to be explained by a genomic mechanism (1 13). 
The Physiological Effects of Glucocorticoids 
Cortisol is essential for life as human beings cannot survive without it. 
Total adrenalectomy without glucocorticoid replacement will result in death 
eventually (1 14). This hormone is ubiquitous affecting cardiovascular function, 
immune response, metabolism, muscle formation, behavior and almost all tissues. 
Basal levels of glucocorticoids, maintained by ACTH through negative feedback 
regulation modulate a variety of processes in the resting state. Most of the 
glucocorticoid effects in the resting state is termed permissive because they 
permit other hormones and factors to accomplish their function. Glucocorticoids 
increase the level of glucose by protein catabolism. It increases total body fat at 
the expense of protein. 
They enhance water diuresis by preserving the rate of glomerular filtration. 
They increase vascular responsiveness and modulate central nervous system 
function. In addition, glucocorticoid hormones decrease lymphocytes, basophils 
and eosinophils while increasing neutrophils. Thus, these hormones have effect on 
immune response, CNS and renal function. 
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However, high levels of cortisol in response to stress may inhibit protein 
matrix formation leading to osteoporosis, and increased production of gastric acid 
which increases the formation of peptic ulcers. The pharmacological effects of 
glucocorticoids refer to their anti-inflammatory and anti-allergic actions. 
Glucocorticoids reduce inflammation by decreasing vascular permeability, 
stabilizing lysosomal membrane, inhibiting kinin production, migration and swelling 
of cells. The anti-allergic effects of cortisol is due to the inhibition of antibody 
production through lympholysis and histamine release. Therefore the excess 
production or administration of glucocorticoids results in a series of 
pathophysiological effects, the most dominant effect being hypertension. Since 
the introduction of the synthetic glucocorticoids in clinical use for a variety of 
disorders, hypertension has been observed as a major complication of long-term 
steroid therapy. It has been demonstrated that cortisol infusion increases blood 
pressure in humans (11)  and hypertension is a common complication in patients 
with Cushing's Syndrome (2). In addition, short-term administration of ACfH to 
normal and hypertensive subjects raised their blood pressure, but not in patients 
with Addison's disease ( 1 15) indicating an important role of cortisol production in 
hypertension. The synthetic glucocorticoid agonist prednisone when given to 
postrenal transplant patients has a direct correlation between the level of arterial 
pressure and the dose ( 1 16). The hypertensive effects of synthetic glucocorticoids 
tend to be species specific. Dexamethasone administration induces hypertension 
in rats (5, 1 17, 1 18) but not in sheep (1 19). However, ACfH infusion quickly 
raised the blood pressure in sheep while cortisol, aldosterone or 
deoxycorticosterone (DOC) had far less hypertensive effect (11) .  
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The Characteristics of Glucocorticoid-Induced Hxpertension 
Glucocorticoid-induced hypertension is not affected by a reduction in renal 
mass or dietary salt intake (120, 121). Rats fed a high or low salt diet develop 
glucocorticoid hypertension (120). Dietary salt restrictions failed to abolish 
glucocorticoid-induced hypertension and only lowered blood pressure slightly 
( 121) .  This model of experimental hypertension occurs without hypokalemia or 
suppression of the renin-angiotensin system. In fact, studies show that 
glucocorticoids increase angiotensinogen secretion ( 122) as well as the renin 
concentration (123). 
Glucocorticoid treatment is associated with increased water consumption, 
urinary output and sodium excretion (natriuresis) resulting in a negative 
sodium balance (5, 125). However, hematocrits of rats with glucocorticoid excess 
hypertension are lower, suggesting an increase in plasma volume (124) . One of 
the hallmarks of experimental glucocorticoid-induced hypertension using 
dexamethasone is a great reduction in body weight caused mainly by skeletal 
muscle catabolism. Glucocorticoid-induced hypertension is also characterized by a 
rapid increase in blood pressure which is observed within a week of steroid 
administration (5,125). 
Though excess glucocorticoids are known to increase arterial blood 
pressure, the biochemical mechanisms by which they induce and maintain 
hypertension are unclear. Several factors have been implicated in the actual 
pathogenic mechanisms such as enhanced response of vascular smooth muscle to 
pressor agents (126), activation of the renin-angiotensin system (127), fluid 
movement from intracellular to extracellular compartments (121) among others. 
Possible Mechanisms of Glucocorticoid-Induced H)lJertension 
1 .  Electrolyte Balance 
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Glucocorticoid-induced hypertension does not require high dietary salt­
intake (unlike mineralocorticoid-induced hypertension) (120). However, other 
studies using the naturally occurring glucocorticoid cortisol or corticosterone, have 
shown that dietary salt restriction reduced the rise in blood pressure although it 
did not totally prevent it (128). This observation has been explained by the fact 
that cortisol and corticosterone possess both glucocorticoid and mineralocorticoid 
actions and may raise blood pressure by both mechanisms. Free cortisol has 1 % 
to 2% the affinity of aldosterone for mineralocorticoid receptors in the kidney 
(129). Thus, if cortisol exceeds the binding capacity of binding globulins and 
glucocorticoid receptors, the free cortisol could contribute to mineralocorticoid 
activity. This has been observed as a possible occurrence in some patients with 
Cushing's disease (1). On the other hand, synthetic glucocorticoid agonists such as 
dexamethasone (5,130) and RU 26988 (131) have virtually no mineralocorticoid 
activity and yet cause experimental hypertension. In fact, dexamethasone has 
antimineralocorticoid effect in the rat ( 132) but still raises blood pressure 
indicating that salt intake and thus, electrolyte balance is not essential for 
glucocorticoid hypertension and therefore other mechanisms may be involved. 
2. Fluid Compartmentalization 
Administration of glucocorticoids causes fluid shift from the intracellular to 
the extracellular compartments thereby increasing the extracellular fluid volume 
( 121). Glucocorticoids activate cell membrane Na+K+ ATPase, an enzyme which 
promotes the exchange of sodium ions from the cell for potassium ions outside the 
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cell. The extrusion of Na+ from the cell is followed by water increasing the 
volume of the extracellular compartment. The Na+/K+ APase activity is 
increased in erythrocytes of patients with Cushing's Syndrome (133) and those 
treated with ACfH (134). Glucocorticoids increase NA+/K+ ATPase in human 
erythrocytes (135) and in myocardial tissue of SHR and normotensive rats (136). 
Thus, in spite of a negative salt balance, there is a shift of water from inside to the 
outside of the cell resulting in hypervolemia. The immediate effect of prolonged 
hypervolemia will be increased cardiac output which may ultimately result in 
increased peripheral resistance through autoregulatory mechanisms and hence 
hypertension. However, it has been observed that the increase in extracellular 
fluid volume does not correlate well with the increase in arterial pressure (137). 
Since glucocorticoid-induced hypertension cannot be fully accounted for by 
hypervolemia, other mechanisms may be contributing. 
3. Renin-Angiotensin System 
Inhibition of the renin-angiotensin system (RAS) in glucocorticoid-induced 
hypertension reduces the high blood pressure (138,139). This indicates the role of 
the RAS in this model of hypertension. Glucocorticoids stimulate and maintain 
the action of the RAS in contrast to suppression of this system by the actions of 
mineralocorticoid. The formation of the renin substrate angiotensinogen is 
induced in the liver by glucocorticoids (140). The level of plasma angiotensinogen 
is raised in patients with Cushing's Syndrome (122) and in experimental models of 
glucocorticoid hypertension (1 17). Angiotensinogen is catalyzed by renin to form 
angiotensin I (AI) which is then converted to angiotensin II (All), by the 
converting enzyme produced by the lungs. Glucocorticoids maintain this lung 
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converting enzyme as adrenalectomy reduces the level of the enzyme appreciably 
which is restored by dexamethasone but not mineralocorticoid replacement (141). 
In all, the angiotensin formation has been reported to be increased by about 40% 
due to glucocorticoid actions ( 123). On the other hand, others have observed that 
adrenalectomy had no significant effect on the in vivo conversion of AI to All 
( 142). Though in the normal subjects cortisol excess reduces plasma renin 
concentration due to increased plasma volume, the plasma renin activity (PRA) 
may be low, normal or elevated in Cushing's Syndrome patients ( 143, 144). 
Administration of the All antagonist saralasin or the converting enzyme inhibitor, 
captopril, decreases pressure in experimental glucocorticoid hypertension 
(117,138, 139). When captopril is administered simultaneously with excess 
glucocorticoids, hypertension is delayed but not fully prevented (145). Inhibiting 
the RAS in patients with Cushing's Syndrome has given inconsistent results ( 146-
148). Patients with high PRA showed markedly reduced arterial pressure, 
however, the pressure is still higher than normotensives (148). Therefore, the 
RAS may participate in glucocorticoid-induced hypertension but it does not 
entirely account for the elevation in arterial pressure observed. 
4. Vascular Smooth Muscle Reactivity 
Glucocorticoids may induce hypertension by enhancing the response of 
vascular smooth muscle (VSM) to pressor agents such as catecholamine and other 
adrenergic agonists (114). It has been shown in normal human subjects ( 149) and 
several animal species (150-152) that glucocorticoids increase vascular 
responsiveness to alpha-adrenergic amines. On the other hand, lack of cortisol 
diminishes cardiovascular sensitivity to pressor substances leading to hypotension 
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( 1 14). Patients with adrenal insufficiency are hypotensive and resistant to pressor 
agents unless treated with adrenal steroid hormones ( 153). In experimental 
animals with bilateral adrenalectomy, VSM is insensitive to vasoconstrictors unless 
pretreated with glucocortiocids ( 154). This led to the hypothesis that 
cardiovascular collapse in adrenal crises may be partially due to insensitivity of 
VSM to vasoconstrictor agents ( 155). 
The type of glucocorticoid agonist and dose administered are important 
factors in potentiating the pressor response of VSM to a particular vasoactive 
substance. Cortisol administration to normal subjects increases the pressor 
response to phenylpherine but not to AIl ( 149). Dexamethasone given in 
experimental glucocorticoid hypertension enhances VSM response to NE (150) 
but when methylprednisolone is given, the VSM pressor response to NE or AIl 
was not enhanced (1 17, 139). However, selective glucocorticoid deficiency reduces 
pressor response to NE and AIl ( 142). The antagonism of endogenous 
glucocorticoids by RU 486 result in reduced pressor response to angiotensin II 
(Ail) and norepinephrine (NE (125). 
Thus, the normal endogenous glucocorticoid concentration (within 
physiological range) may be required for normal vascular responsiveness but 
whether excess glucocorticoids corresponds to a direct increase in responsiveness 
to pressor agents leading to hypertension needs to be proven. 
Specific glucocorticoid receptors are found in brain (156), cardiac and 
vascular tissues ( 157) of animals and the arterial smooth muscle cells in humans 
( 158). However, glucocorticoids may have different actions in different tissues as 
proteins induced by glucocorticoids are tissue-specific (159). It has been 
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postulated that glucocorticoids may increase VSM responsiveness to epinephrine 
(E) by inhibiting the enzyme catechol-o-methyl transferase (COMT) thereby 
preventing the breakdown of E (160). The reason for this postulation stems from 
the observation that cortisol potentiates the pressor effect of E and not NE in 
experimental animals ( 160). Other possible explanation for glucocorticoid induced 
VSM responsiveness include increased Na+K+ pump activity and structural 
changes at the vascular wall ( 1 14). Although increased pressor responses are 
observed in VSM in vitro these local effects are not seen in vivo after 
glucocorticoid treatment. In humans, it has been reported that administering 
glucocorticoids increase pressor response to NE and E ( 152) whereas others 
observed no effect ( 1 17, 161). These inconsistencies between in vitro and in vivo 
glucocorticoid-induced vascular response may be explained by the compensatory 
cardiovascular reflexes which might occur in vivo. Thus, the literature on VSM 
reactivity as a possible mechanism for glucocorticoid hypertension is inconclusive. 
5. Renal Function 
The role of adrenocorticosteroid hormones in the maintenance of normal 
renal function is well established (162). In adrenal insufficiency (Addison's 
diseases) both glomerular filtrate rate (GFR) and renal blood flow (RBF) are very 
low ( 1 1) .  Glucocorticoids increase GFR while total RBF remains constant thereby 
increasing the filtration fraction (GFRJRBF) ( 163). This may explain why there is 
an exaggerated natriuresis in patients with Cushing's Syndrome ( 164, 165) and, also 
in normal individuals fed a high dietary salt intake and given cortisone ( 165). 
Unfortunately, how these changes in renal function contribute to glucocorticoid 
hypertension are not known. 
6. Prostaglandins 
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The production of the vasodilator prostaglandins by white blood cells is 
inhibited by glucocorticoid action (150). It has been shown in vitro that 
glucocorticoids affect the biosynthesis of prostaglandins by inhibiting the release of 
arachidonic acid from phospholipids ( 166). They induce a protein, macrocortin, 
which inhibits phospholipase A2, the enzyme that releases arachidonic acid from 
phospholipids. In arterial tissue, glucocorticoids directly inhibit the synthesis of 
prostacyclin ( 167) . Prostaglandin E2 (PGEz) excretion from the kidneys is also 
reduced (150). Thus, glucocorticoids might raise blood pressure through the 
inhibition of phospholipase A2 leading to a reduction in the activity of vasodilator 
protanoids. Dexamethasone-induced hypertension was prevented by the 
administration of a fish-oil diet which increases the formation of vasodilator 
prostaglandins (168). On the other hand, in vivo studies show that glucocorticoids 
have little effect on prostaglandin formation (169). In fact, glucocorticoids may 
increase the synthesis of some prostanoids by renal tissues (167, 170). In addition, 
glucocorticoids might increase synthesis of prostaglandins through its lipolytic 
effect on triglycerides which increases arachidonic acid (170). Therefore, 
prostaglandin deficiency as mechanism of glucocorticoid-induced hypertension is 
not conclusive. 
7. Other Cardiovascular Effects of Glucocorticoids 
Glucocorticoids may also control the sympathoadrenal function by 
stimulating the production of the enzyme, phenylethanolamine-N­
methyltransferase (PMNT) which catalyzes the conversion of NE to E. Inhibition 
of PMNT ( 171) or blockade of sympathetic ganglion ( 1 17) reduces glucocorticoid-
induced hypertension. Also, cardiac and lung beta receptors are increased by 
glucocorticoid treatment (172). However, there is no evidence that there is an 
increase in catecholamine production or sympathetic nervous system activity by 
glucocorticoid treatment. 
Actions of Mineralocorticoids 
24 
The main action of mineralocorticoids on blood pressure is due to their 
effects is on salt and water balance. They increase sodium retention which raises 
the extracellular fluid volume and if prolonged, may increase the cardiac output 
leading to a high total peripheral resistance via Guyton's model of autoregulation 
(173). The actions of mineralocorticoids stimulate sodium transport from 
secretory cells such as the renal tubular cells, salivary gland, sweat glands and 
gastrointestinal tract. Increased sodium transport from the renal tubular cells into 
the extracellular fluid creates a negative intraluminal pH and subsequently 
potassium and hydrogen ions are excreted (3). The major mineralocorticoid is 
aldosterone. 
Aldosterone secretion is regulated by the renin-angiotensin system and 
increases when extracellular volume decreases. Renin, produced by the 
juxtamedullary apparatus in the kidney when renal artery pressure is low, converts 
the substrate angiotensiongen produced by the liver to angiotensin I (AI). A 
converting enzyme synthesized in the lungs catalyzes the conversion of AI to All. 
All stimulates the synthesis of aldosterone from the zona glomerulosa of the 
adrenal cortex. The exogenous administrtion of aldosterone induces hypertension 
in experimental animals (9, 10), as well as in humans (8). Primary aldosterone 
which can be due to adrenal adenoma (APA), adrenal carcinoma or bilateral 
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hyperplasia resulting in over production of aldosterone, is associated with 
hypertension (3). Another mineralocorticoid well studied in mineralocorticoid­
induced hypertension is deoxycorticosterone (DOC). In congenital adrenal 
hyperplasia, 1 18 and 17cr-hydroxylase deficiency resulting in excess DOC 
production is also associated with hypertension (3). Furthermore, administering 
DOC to rats ( 174), pigs (179), dogs (176) and humans (177) caused a blood 
pressure increase. Unlike aldosterone, DOC is regulated by the ACTH levels and 
has been shown that in Cushing's Syndrome patients, the excessive production of 
ACTH results not only in hypersecretion of cortisol but also of DOC (1) .  
Besides aldosterone and DOC, other mineralocorticoids have been shown 
to induce hypertension (1) .  A potent mineralocorticoid, 19-nor DOC, induces 
hypertension in rats ( 178) and is suspected of playing a major role in hypertension 
developed by SHR (87). 
Characteristics of Mineralocorticoid Hypertension 
1 .  Unlike glucocorticoid-induced hypertension, mineralocorticoid-
induced hypertension is dependent on dietary salt intake and reduced renal mass 
(124). Thus, a well-established model of mineralocorticoid-induced hypertension 
in rat is DOC administration combined with high salt intake and reduced renal 
mass. 
2. Mineralocorticoid-induced hypertension is characterized by increased 
sodium retention resulting in hypernatremia followed by increased water retention. 
3 .  Reduced hematocrit indicating increased plasma fluid. 
4. Increased fluid intake (Polydipsia). 
5 .  Increased body weight. 
6. Increased potassium and hydrogen excretion resulting in 
hypokalemia and alkalosis, respectively. 
7. Increase in blood pressure with a slow onset. 
8. One of the most consistent biochemical effects of excess 
mineralocorticoid is suppression of the renin-angiotensin system via a negative 
feedback mechanism. 
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Whereas, mineralocorticoids increase renal sodium and fluid reabsorption 
resulting in increased extracellular fluid volume and gain in body weight, excess 
glucocorticoids is associated with a negative sodium balance and great reduction in 
body weight ( 124). However, the end result is the same, that is, increased blood 
pressure. Thus, the mechanisms employed by these two steroids in inducing 
hypertension are believed to be different although the actual pathogenic 
mechanisms responsible for the development and maintenance of steroid-induced 
hypertension are not known. 
Possible Mechanisms of Mineralocorticoid Hypertension 
1. Electrolyte Balance 
The actions of mineralocorticoids on ion transport lead to increased sodium 
retention and then increased extracellular fluid volume resulting in increased 
cardiac output (8). The autoregulatory mechanisms set off by increased cardiac 
output returns the cardiac output to a normal level but at the expense of 
increased total peripheral resistance which leads to a rise in arterial pressure 
( 173). Dogs treated with metyrapone ( 17) and pigs implanted with 
deoxycorticosterone acetate ( 18) suggest that the elevation of blood pressure is 
associated with variable relative elevation in cardiac output and peripheral 
resistance. 
2. Vascular Reactivity 
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Excess aldosterone causes increased sodium retention and intracellular 
sodium content in tissues which may lead to increased vascular reactivity and 
contributing further to blood pressure elevation. Aldosterone may stimulate 
passive and sodium pump-dependent Na+ transmembrane movements in vascular 
smooth muscle (9). These effects are blocked in a dose-dependent fashion by 
mineralocorticoid antagonists. Several studies have shown that mineralocorticoid 
administration enhances vascular sensitivity to vasoactive substances such as 
epinephrine and angiotensin II (179) which occurs prior to increase in peripheral 
resistance (174). Evidence for this proposed mechanism stems from the 
observation that high affinity specific binding mineralocorticoid receptors are 
present in the cytosol of vascular smooth muscle cells ( 180). Though not 
conclusive, this suggests the possibility of a direct effect of mineralocorticoids on 
VSM. The most convincing evidence is from the result of Komel et al. ( 181). 
They showed the existence in the arterial wall of an in situ molecular mechanism 
for mineralocorticoids. However, there is evidence that the action of steroid 
hormones on VSM is indirect (182). 
3. Central Nervous System (CNS) 
It has also been postulated that since high affinity, specific binding sites for 
aldosterone are found in various parts of the brain associated with blood pressure 
regulation, excess mineralocorticoids might have a direct effect on the central 
nervous system when they bind to these receptors (183,184). 
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Intracerebroventricular infusion of low doses of aldosterone induces hypertension 
in mononephrectomized saline drinking Sprague-Dawley rats and the simultaneous 
infusion of prorenone, a potent and specific mineralocorticoid antagonist, blocked 
the pressor effects of aldosterone ( 186). This study provides a strong evidence for 
a direct hypertensinogenic effect of aldosterone in the CNS. Other studies have 
shown that Jesioning the anteroventral part of the hypothalamus (AV3V) prevents 
the development of mineralocorticoid-induced hypertension (179). It is thought 
that mineralocorticoids may change the intracellular sodium content of these 
hypothalamic cells affecting the release of agents such as vasopressin that 
stimulate drinking or influence vascular responsiveness ( 179). 
Another possible mechanism of aldosterone is through the release of atrial 
natriuretic factor (ANF) to combat extracellular volume increase induced by 
mineralocorticoid actions ( 186). The biochemical mechanisms of ANF are not 
clear but it is possible some of its actions raises the blood pressure. The actions 
of ANF are complex but it is believed to act as an Na+K+ ATPase inhibitor 
counteracting the effects of aldosterone in the kidney (186). ANF stimulates an 
increase in the CGFR and prevents renal reabsorption of sodium and water, thus, 
acting as a powerful diuretic ( 187). In addition, ANF blunts renin release and 
has been shown to lower plasma renin levels in dogs ( 187). It also blocks the 
synthesis and release of aldosterone (188, 189) and vasopressin (190). These 
effects of ANF actions promote diuresis and natriuresis and block the production 
and actions of the RAS and vasopressin and other pressor agents (187). Although 
these should lower the blood pressure, there is evidence ANF may ultimately lead 
to increased blood pressure (191). The natriuretic hormone not only inhibits the 
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sodium pump in the kidney, but in other types of cells including those of the VSM 
(192). Blaustein (193) has proposed that inhibition of Na+K+ ATPase activity 
leads to increased intracellular sodium which reduces the sodium gradient thus the 
Na+/Ca2+ exchange fails to operate raising the intracellular calcium ion 
concentration. Calcium ions are responsible for muscle contraction and an 
increase will make the VSM contract more readily. Long periods of enhanced 
arteriolar contraction may lead to structural changes in the vascular walls with a 
rise in arterial pressure. In addition, changes in the ionic content of smooth 
muscle cells can increase contractility by enhancing their response to 
vasoconstrictive agents. Haddy and associates (144) observed that pump 
suppression increased blood vessel sensitivity to norepinephrine with elevation in 
blood pressure. Several researchers have observed high intracellular sodium ion 
concentration in various cell types from humans (193-195) and animals (196, 197) 
with hypertension. Takeda and Miyamori has reported a significant increase in 
the basal levels of plasma ANF in essential hypertensive subjects as compared 
with age-matched normotensives (191) . On the contrary, other researchers failed 
to demonstrate any significant difference in plasma ANF levels between 
hypertensive and normotensive groups (198-200). Thus, the role of ANF in the 
pathogenesis of hypertension is inconclusive. 
In summary, the pathogenic mechanisms contributing to steroid-induced 
hypertension are numerous and undefined. Overall, it is likely that steroid 
hormones may exert their effect by binding to their receptor (receptor-mediated 
genomic actions) but also they can act through non-receptor mediated events 
termed the "hypertensinogenic" action ( 1 19). These could explain the reason why 
the possible mechanisms in steroid-induced hypertension are not sufficient to 
account for the rise in blood pressure observed. 
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RATIONALE 
Since excess mineralocorticoids and glucocorticoids are known to induce 
hypertension in several diseases, the therapeutic value of adrenocortical steroid 
hormone antagonists in the clinical treatment of such diseases is very important. 
Unfortunately, research in this area has been slow because there are no potent 
and specific antiglucocorticoids or anti-mineralocorticoids available. Those 
available are limited in their experimental and clinical usefulness as they often 
exhibit some agonist activity (201) or cross-reactivity with other steroid hormone 
receptors (201,202). Glucocorticoid antagonists may be active only in vitro and not 
in vivo (201) while mineralocorticoid antagonist such as spironolactone has serious 
endocrinological side effects due to its high affinity for the androgen and 
progesterone receptors (202). Thus, since the introduction of these steroid 
hormone antagonists, the search for new and pure glucocorticoid antagonists 
which are active both in vitro and in vivo and mineralocorticoid antagonists with 
less endocrinological side effects has been going on. Recently, researchers at 
Roussel-Uclaf have synthesized an exciting multifaceted steroid hormone 
antagonist known as RU 4861 or mefiprestone which is the first known pure 
1RU 486 [17-Hydroxy-ll (4 dimethyl aminophenyl-l») 17(lpropynyl)-estra-4-diene 3 one). 
3 1  
glucocorticoid antagonist which is active not only in vitro but also in vivo without 
any agonist effects (203). They have also synthesized a new mineralocorticoid 
antagonist designated RU 267522. Scientists at Schering (West Germany) have 
recently synthesized a novel antimineralocorticoid compound known as 
mespirenone3. 
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Since these new and potent antagonists are now available, it is of great 
clinical and scientific interest to study its therapeutic potential in vivo. Antagonists 
for steroid hormones are important not only for clinical use but also as tools for 
probing the molecular mechanisms of hormone action about which only little is 
known. It has previously been shown in this laboratory that RU 486 successfully 
prevents the hypertension induced by the long-term administration of 
dexamethasone (5). Thus, the long-term in vivo effect of RU 486 was studied in 
rats to show the significance of this drug. However, the specificity of RU 486 as 
an antiglucocorticoid in preventing adrenocorticoid-induced hypertension is not 
known. Thus, this study was initiated to investigate if RU 486 possesses some 
mineralocorticoid agonist or antagonist properties. On the other hand, no in vivo 
studies have been done with the newly synthesized mineralocorticoid antagonists, 
RU 26752 and mespirenone on steroid-induced hypertension until now. Though 
in vitro studies have shown increased affinity of these compounds for the 
mineralocorticoid receptor (MR) over the clinically used antimineralocorticoid, 
spironolactone, surprisingly no studies have been done to follow up the potency of 
2RU 2675 (7«-propyl-3-oxo-17«-pregn-4-ene 21, 17-carbolactone). 
3Mespirenone (7« -acetylthio-15 p -methylene-3-oxo-17 «-pregna-1,4-diene-21, 17 -carbolactone). 
these drugs to show if increased in vitro affinity for the MR is fairly correlated 
with their in vivo pharmacological action. Therefore, for the first time, in vivo 
studies have been conducted to evaluate the antimineralocorticoid effect of RU 
26752 and mespirenone in rats. 
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The goal of this work was to investigate the antihypertensive effect of these 
novel antagonists since the most common complication of excess adrenocortical 
steroid hormone production is hypertension. The specific aims were: 1) to 
evaluate the specificity of RU 486 as an antiglucocorticoid by assessing its effect 
on mineralocorticoid-induced hypertension; 2) to study the long-term in vivo effect 
of the newly synthesized mineralocorticoid antagonists RU 26752 and mespirenone 
on mineralocorticoid-induced hypertension in rats to establish the significance of 
these compounds; 3) To assess if RU 26752 and mespirenone are specific for 
mineralocorticoid-induced hypertension or if they also prevent glucocorticoid­
induced hypertension in rats; 4) to elucidate whether glucocorticoid and 
mineralocorticoid antagonists are effective in the treatment of the genetic model 
of hypertension; namely, the spontaneously hypertensive rat (SHR). In the 
literature, there are several reports implicating adrenocorticosteroid hormones in 
the development and maintenance of the SHR (82,85-87). The study of the SHR 
is also important because it is thought to be the closest model of experimental 
hypertension to the human essential hypertension. 
MATERIALS AND METHODS 
Deoxycorticosterone acetate (DOCA) d-aldosterone and dexamethasone 
were purchased from Sigma Chemical Co. (St. Louis, MO). Aldosterone and RU 
26752 custom-made pellets were obtained from Innovative Research of America 
(Toledo, OH), RU 38486 and RU 26752 (for injection, not pellets) were a gift 
from Roussel-Uelaf Pharmaceutical Company (France). Mespirenone was also 
donated by the Schering Chemical Company (Germany). Olive oil used as the 
vehicle was of the Pompeian brand. Male Sprague-Dawley rats (CD strain) 
weighing between 250-300g and six-week-old male spontaneously hypertensive rats 
(SHR) were obtained from Charles River Breeding Laboratories. The rats were 
housed in individual metabolic cages under environmentally controlled conditions 
exposed to 12 hours of light and 12 hours of darkness. Rats were given Purina rat 
chow and water ad libitum. Institutional Animal Care and Use Committee 
guidelines were followed to prevent pain during surgical procedure and throughout 
the experimental period. 
General Methodology 
Blood Pressure Measurements 
Systolic blood pressure of all rats was determined by the tail-cuff method 
(204). An l ITC photoelectric pulse pressure transducer (MOD 29 pulse 
amplifier) (Woodland Hills, CA), a Grass polygraph (Model 7) (Quincy, MA), a 
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Narco automatic cuff inflator and rat temperature control unit (Houston, TX) 
were used. Animals were given at least 30 minutes to get accustomed to the 
constraint unit before pressure recordings were made. To get reliable data, 
recordings were done when animals were obviously calm as stress will increase 
glucocorticoid levels which can alter the blood pressure. In addition, taking into 
consideration the fact that steroid hormone release follows a circadian rhythm, it 
became imperative for recordings not to be done at the peak time (that is at 4 
p.m.) and also each set of recordings should be done always at the same time of 
the day. Temperature around the rat tail was maintained at 30°C throughout the 
recording period. The systolic blood pressure (SBP) was taken. The SBP was 
taken only when the reading was stable. The SBP was considered stable when six 
consecutive clear readings were the same or were within 5 mmHg of each other. 
The blood pressure represent the average of at least six measurements for each 
rat per week. Blood pressure measurements were done once every week during 
the experimental period. Calibration of the drive amplifier on the Grass 
polygraph to set the baseline was done before each set of measurements. 
All rats were weighed on the same day after blood pressure measurements 
had been taken. To keep stress to a minimum, rats were never weighed or 
injected before blood pressure recordings were done. 
Injection Regimen 
Olive oil was used as the vehicle. Injections were given intramuscularly or 
subcutaneously on the leg of the rats. Precaution was taken to avoid bleeding as 
bleeding would have caused leakage of the solution. Injections were not given 
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consecutively on the same leg so as to prevent swelling. To ensure even 
concentration of the injection solution, the solutions were thoroughly stirred just 
before each animal was injected. 
Fluid Consumption and Urinary Output Recording 
Fluid intake and urinary output of the rats were taken on two consecutive 
days each week during the experimental period. Animals were transferred to 
metabolic cages and had free access to Purina rat chow and water or 0.9% saline 
depending on the experimental model of steroid-induced hypertension. The fluid 
was in a graduated bottle so that fluid intake was easily determined. Graduated 
plastic bottles were attached to the bottom of the metabolic cages to determine 
urine volume. Readings were taken over a 24-hour period thus taking into 
account the circadian nature of steroid hormone release and their influence on 
fluid intake and urinary output. 
An average of the values on two consecutive days represent the fluid intake 
and urine output of each group. Metabolic cages needed to be cleaned after each 
set of collection or the connection from cage to urine collecting bottle could be 
blocked with chow and fecal material thus underestimating the urine volume. 
Samples of urine were frozen and later used in the determination of 
sodium and potassium concentration by flame photometry. Some values obtained 
were so variable even within groups that they were not useful in drawing any 
conclusions from them and therefore were not included in these studies. 
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Histological Preparation of Organs 
At the end of the experimental period, the rats were anesthetized with 
carbon dioxide and killed by cervical dislocation. The liver, heart, kidney and 
thymus were quickly removed and weighed. Heart and kidney tissues were 
immediately placed in buffered formalin. Tissue sections were cut of the heart 
and kidney and stained with Masson's trichrome which is a fuchsin stain. This 
stain was used to identify areas of myocardial degeneration of heart tissues and 
interstitial nephritis of kidney tissues. The severity of myocardial degeneration 
and interstitial nephritis was indicated by the extent of fuchsinophilia. 
Analysis of Data 
All the data collected were analyzed statistically by the two-way analysis of 
variance (ANOVA) followed by the Scheffes' test for multiple comparisons using 
the STAT computer program. All graphs were done by Sigma plot. 
CHAPTER 1 
The Role of the Glucocorticoid Antagonist RU 486 in 
Adrenocorticosteroid-Induced Hypertension 
Abstract 
Previously, we have shown that RU 486 successfully prevented the 
hypertension induced by the long-term administration of dexamethasone to male 
Sprague-Dawley rats (5). In the present study, we determined the effect of RU 
486 on two other experimental models of hypertension in the rat, namely, the 
deoxycorticosterone acetate (DOCA)-salt and the spontaneously hypertensive rats 
(SHR). Uninephrectomized saline-drinking male Sprague-Dawley rats were 
divided into 3 groups and given either 0.2 ml olive oil (control), I mg DOCA, or I 
mg DOCA+ 10 mg RU 486 dissolved in 0.2 ml olive oil every third day for a 
period of three weeks. Within a week of steroid administration, there was a sharp 
increase in the systolic blood pressure (SBP) in the DOCA-salt (170 ± 2.8) and 
DOCA + RU 486 (173 ± 1.6) treated rats over the control rats (127 ± 3.5) which 
remained elevated throughout the experimental period. There was significant 
difference in the water consumption and urinary output between the control and 
DOCA + RU 486 treated rats. In the experiment involving the SHR, the rats 
were divided into groups I, II, and III and given 0.2 ml olive oil (control), 1 mg 
RU 486, and 5 mg RU 486 dissolved in 0.2 ml olive oil respectively, for 3 weeks. 
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Instead of a decrease in the blood pressure as might be expected, surprisingly RU 
486 enhanced it significantly within three weeks of drug administration. Control 
and 5 mg RU 486 treated rats had SBP of 153 ± 1 .7, and 172 ± 2.5, respectively, 
during the three-week experimental period. Water intake, urinary output, body 
and organ weights were comparable in all groups. It is concluded that RU 486 
has no effect on DOCA-salt model of hypertension but interestingly, elevates the 
hypertension in the SHR. 
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Introduction 
Until recently, antiglucocorticoids available were active only in vitro or 
weakly active in vivo (201). A new glucocorticoid antagonist denoted RU 486 is 
the first known potent anti glucocorticoid active in vitro as well as in vivo in 
different target tissues (203) .  RU 486 given orally (205), intraperitoneally (206) 
and intramuscularly (207) results in antiglucocosticoid responses. Early studies of 
RU 486 treatment in patients with Cushing's Syndrome showed a partial or 
complete reversal of hypokalemic alkalosis found in these patients which is due to 
the mineralocorticoid activity of excess cortisol produced in these patients (208) . 
This has led to the speculation that RU 486 and/or some of its metabolites might 
have some antimineralocorticoid activity. This speculation is valid because steroid 
hormone antagonist often cross-react with other hormone receptors. RU 486 not 
only binds the glucocorticoid receptor but has a strong affinity for the 
progesterone receptor and to a lesser extent to the androgen receptor (209). But 
in vitro studies have shown negligible cross-binding of RU 486 with the rat renal 
mineralocorticoid receptor (209) . Since progesterone possesses 
antimineralocorticoid activity (210), it is possible that RU 486 may have some 
mineralocorticoid agonist or antagonist activities dependent on its antiprogestin 
properties. In addition, RU 486 may exert its apparent antimineralocorticoid 
effects via its antagonism of glucocorticoid action. Naturally occurring 
glucocorticoids may potentiate the mineralocorticoid sodium retention effect by 
increasing the extracellular volume and the glomerular filtration rate (GFR) 
(121, 163). A glucocorticoid antagonist such as RU 486 might then show 
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antimineralocorticoid activity by decreasing the ECF and GFR and thus, amount 
of water and sodium delivered to the distal and collecting tubules. Therefore, RU 
486 may be exhibiting anti-mineralocorticoid activity indirectly through its 
antagonism of the actions of these other hormones. Studies show that depending 
on the response examined, RU 486 can act both as a suboptimal or optimal 
antagonist. Steroid hormone antagonists may possess partial agonist activity and 
such antagonists are referred to as "suboptimal inducer" or a partial agonist­
antagonist" and their action is known as "suboptimal antagonism." An optimal 
antagonist is therefore devoid of agonist activity and it is able to antagonize 
completely the effects of an optimal agonist. Some studies have reported that RU 
486 exhibits no agonist activity even when administered in large doses (see 211  for 
review) while others have observed mild glucocorticoid agonist activity (212). 
Therefore, RU 486 may have some mineralocorticoid agonist or antagonist 
properties dependent or independent of its antiglucocorticoid and antiprogestin 
properties. Although in vitro studies have shown negligible cross-binding of RU 
486 with the rat renal mineralocorticoid receptors (209), this may not correlate 
well with its in vivo potency as the compound may be modified by its 
pharmacokinetic and metabolic activities that may produce reactive metabolites 
which determines its overall biological activity. 
Previously, we have shown in this laboratory that RU 486 was able to 
prevent the hypertension induced by long-term administration of dexamethasone 
to Sprague-Dawley rats (5). However, the specificity of RU 486 in preventing 
adrenocorticoid-induced hypertension is not known. For example, could RU 486 
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have any agonistic or antagonistic mineralocorticoid effect in the rat? Therefore, 
the specificity of RU 486 in preventing glucocorticoid-induced hypertension was 
investigated by studying its effect on two other models of experimental 
hypertension, namely, the DOCA-salt and the spontaneously hypertensive rats 
(SHR). 
Materials and Methods 
Blood pressure measurements and the weights of the rats were taken on 
days 0, 7, 14 and 21. For initiating DOCA-salt-induced hypertension, the Sprague­
Dawley rats were right uninephrectomized under ether anesthesia. A week after 
uninephrectomy, the animals were divided into three groups of eight rats each 
(n= 8) and the baseline blood pressure measurements were taken. Steroid 
administration was by intramuscular injections every third day for 18 days (total 7 
injections). Group I (n=8) received 0.2 ml olive oil/300 g, Group II (n= 8) 
received 1 mg DOCN300 g and Group III (n=8) received 1 mg DOCA + 10 mg 
RU 486/300 g dissolved in 0.2 ml olive oil. The SHR animals were also divided 
into 3 groups and blood pressure taken on days 0, 7, 14 and 21. Injections were 
given intramuscularly every third day for 18 days as above. Group I (n= 8) was 
given 0.2 ml olive oil/ISO g, Group II (n=8) received 1 mg RU 486/150 g and 
Group III (n=8) received 5 mg RU 486/150 g dissolved in 0.2 ml olive oil. 
Fluid consumption and urinary output were recorded on two consecutive 
days each week (total of six recordings). At the end of the experimental period, 
animals were anesthetized with carbon dioxide and sacrificed by cervical 
dislocation. The heart, kidney, thymus and liver were quickly removed and 
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weighed. The heart and kidney tissues were histologically prepared for 
morphological examination. All data collected were analyzed by the two-way 
analysis of variance followed by the Scheffe's test for multiple comparisons. 
Results 
Results presented in Figure 1 demonstrate the effect of RU 486 on 
dexamethasone-induced hypertension (Am. J. PhysioJ. 256:E683) which serves as 
an introduction to this work. Results presented in Figure 2 and Table 1 show that 
within a week of steroid administration, there was a sharp increase in the blood 
pressure in the DOCA-salt treated rats (170 ± 2.8) over the control rats (127 ± 
3.5) which remained elevated over the three weeks of experiment. The 
simultaneous administration of DOCA + RU 486 (173 ± 3.1) was unable to 
prevent or potentiate the hypertension induced by DOCA-salt treatment. 
No significant difference in the weights among the groups was noted during 
this three-week period (Table II). Data shown in Table II demonstrate a 
significant increase in saline consumption in the rats injected with DOCA + RU 
486 (66 ± 3.5) as compared to control rats (41.50 ± 2.0). This was followed by a 
correspondingly higher urine output in the former rats (23 ± 3.2). There was no 
significant difference observed in the weight of kidney and heart among the three 
groups. 
When male SHR were given RU 486 (comparable to those given to DOCA 
+ RU 486 on weight basis) for 3 weeks by injection (Fig. 3 and Table III) instead 
of decreasing the blood pressure, RU 486 significantly increased it ( 172 ± 2.5) 
over the controls (125 ± 2.1). However, RU 486 had no significant effect on body 
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weight, water intake, urinary output and organ weight of the SHR animals (Table 
IV). 
Morphological examination of histologically prepared sections of the heart 
and kidney showed no abnormalities, that is, fuchsinophila of the myocardium and 
renal tissue were considered to be insignificant (data not shown). 
Discussion 
Ru 486 is known to bind strongly to the glucocorticoid receptor with an 
affinity three times higher than the potent glucocorticoid agonist dexamethasone 
(205,209). But it also cross-reacts with the progesterone receptor and slightly with 
the androgen receptor (209). Progesterone prevents glucocorticoid-induced 
hypertension and potentiates natriuresis through its antimineralocorticoid activity 
(210). Since progesterone possesses both antimineralocorticoid and 
antiglucocorticoid properties, this led to the notion that RU 486 may possibly have 
some antagonist or agonist mineralocorticoid activities as well (5). The results 
presented here clearly indicate that RU 486 does not possess mineralocorticoid 
antagonist or agonist properties. The lack of mineralocorticoid antagonist 
property of RU 486 in terms of its prevention of DOCA-salt induced hypertension 
is consistent with other in vitro studies suggesting that RU 486 has no cross­
reactivity with mineralocorticoid receptors (209). According to Teutsch and 
Costerousse the 17a-propynyl side chain provides RU 486 with pure glucocorticoid 
activity devoid of mineralocorticoid activity and thus, this side chain may explain 
the lack of binding of RU 486 to the mineralocorticoid receptor (213). In 
addition, Grunfeld and Eloy (1985) have observed that sodium and potassium 
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balance was not affected by RU 486 treatment in rats which indicates it has no 
mineralocorticoid activity (125). On the contrary, RU 486 administration 
normalized the blood pressure and reversed the hypokalemic alkalosis seen in 
Cushing's Syndrome patients (212). Since glucocorticoid- induced hypokalemic 
effect is thought to be due to the mineralocorticoid activity of endogenous 
glucocorticoids binding to Type I receptors in the kidney, it led to the speculation 
that RU 486 and/or some of its metabolites might possess some 
antimineralocorticoid activity in man (212). Though studies have not been done in 
human kidneys, in vitro studies have shown that RU 486 has negligible cross 
reactivity with the rat kidney mineralocorticoid receptors (209). Due to species 
variability, it is necessary for similar study to be done in humans before any 
conclusive remarks can be drawn. On the other hand, several researchers have 
shown that the potent glucocorticoid agonist dexamethasone, with negligible 
mineralocorticoid activity cross-react with the type I receptors in the brain 
(184,214). However, in vivo physiological mineralocorticoid target tissues such as 
the kidney, intestine and the parotid are highly aldosterone-selective, in contrast 
with the hippocampus and heart (215). Thus, the binding of glucocorticoids to 
type I receptors tends to be tissue specific. In vitro studies have shown high levels 
of IIB-OH steroid dehydrogenase activity in these aldosterone-selective tissues, 
but this enzyme has not been found in the hippocampus (216). This enzyme 
converts glucocorticoids to its ll-dehydro metabolite which has a low affinity for 
the type I receptor (217). This has been postulated as the mechanism by which 
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glucocorticoids are excluded from binding to type I receptors in mineralocorticoid 
target tissues (215). 
Since RU 486 may not bind to kidney mineralocorticoid receptors, it is 
more likely that the apparent antimineralocorticoid activity of RU 486 is not by its 
binding to mineralocorticoid receptors in the rat kidney but rather indirectly 
through its antagonism of glucocorticoid activity. Therefore, an antiglucocorticoid 
preventing increased GFR will decrease the rate by which water and sodium pass 
through the distal and collecting renal tubules and thus decrease water and sodium 
retention giving the illusion of antimineralocorticoid activity. Results from this 
laboratory (5) and others (212,218) have shown that RU 486 prevents the 
transient diuresis and natriuresis induced by glucocorticoid treatment. RU 486 
had no mineralocorticoid agonist property, since RU 486 did not potentiate the 
blood pressure in the DOCA + RU 486 treated rats in spite of a possible increase 
in plasma corticosterone level due to increased ACTH levels. Glucocorticoids 
exert a negative feedback effect on ACTH secretion from the anterior pituitary 
which serves as the major control mechanism of the pituitary-adrenocortical 
system. Studies in humans and other primates have shown that RU 486 was able 
to antagonize the suppressive effect of dexamethasone upon the pituitary-adrenal 
axis (219,220). Thus, ACTH secretion is increased during RU 486 administration. 
RU 486 treatment has been observed to activate the hypothalamic-pituitary 
adrenal axis in rats and monkeys, as well as in humans (see 203 for review). 
Chronic treatment with RU 486 in rats and monkeys resulted in increased ACTH 
levels, adrenal weights and glucocorticoid levels (203). In humans, RU 486 
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administration increased the ACfH secretion only at the times of the day when 
endogenous corticotrophin-releasing hormone (CRH) was high, subsequently, 
glucocorticoid levels were elevated in the early morning hours in Cushing's 
Syndrome patients treated with RU 486 (208). Thus, though the corticosterone 
level might have been increased in the DOCA + RU 486-treated rats, the 
elevation in SBP between these rats and the rats treated with DOCA alone was 
the same. This can be explained by the rationale that there were no receptors 
available for corticosterone to bind as the type I receptor was occupied by excess 
administration of DOCA and the type II by excess administration of RU 486. 
DOCA given in combination with RU 486 resulted in a significant increase 
in saline consumption followed by increased urine output. Mineralocorticoid­
induced hypertension is characterized by increased saline intake. Structures in the 
forebrain such as the anteroventral third ventricle (A V3V region) which is 
involved in the regulation of thirst, sodium homeostasis, blood volume and the 
secretion of arginine vasopressin (A VP) is necessry for mineralocorticoid 
hypertension but not in the SHR (179,221). Lesioning of the AV3V region 
prevents the development of this experimental model of hypertension in rats 
(222) . It is being hypothesized that mineralocorticoids may alter the intracellular 
sodium content of the cells in the A V3V region and affect the release of other 
agents that stimulate drinking. The plasma level of vasopressin is elevated in 
DOCA-salt hypertension (222). The fluid consumption of rats treated with a 
combination of DOCA and RU 486 was even higher than rats treated with DOCA 
alone. In vitro studies have shown that RU 486 down regulates type 1 receptors in 
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the mouse hippocampus (184) . Since angiotensin stimulates fluid intake, RU 486 
seems to behave as a weak agonist centrally (185) and the secretion of 
vasopressin, we are postulating that RU 486 might be acting as an agonist in the 
rat brain, thus potentiating the fluid consumption in these rats. This increase in 
water consumption resulted in increased urinary output without any significant 
change in the weight of the animals. 
Though antiglucocorticoid RU 486 did not prevent the hypertension 
induced by DOCA, surprisingly it enhanced the blood pressure of the SHR. Thus, 
our finding contradicts the conclusion of Hashimoto et al. (85) that corticosterone 
is essential for the development of hypertension in SHR. If this were to be the 
case, RU 486 treated SHR should have shown a reduced rather than enhanced 
blood pressure. It is important to point out that highly variable results have been 
obtained regarding plasma levels of adrenocorticoids in SHR by various 
investigators. Some have reported increased (82) or normal corticosterone (84) 
levels and other have reported increased (86) or decreased aldosterone (226) 
levels. Keeping this in mind, our results are consistent with the observation that 
adrenalectomy of young prehypertensive rats prevented the increase in blood 
pressure and subsequent infusion of aldosterone induced hypertension in these 
rats (81), indicating that mineralocorticoids seem to be more important in the 
induction of hypertension in the SHR model. To explain the enhanced blood 
pressure observed in RU 486-treated SHR, we are postulating that in SHR, RU 
486 was bound to type II receptors blocking glucocorticoid action while type I 
receptors were unoccupied so that the excess corticosterone which might have 
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been produced by RU 486 treatment (through activation of the hypothalamic­
pituitary adrenal axis) could cross-bind to type I to exert biological effects 
including increased blood pressure. This explanation agrees with Funder et al. 
(215) suggesting that in peripheral mineralocorticoid target tissues such as the 
kidney, aldosterone and corticosterone might have similar (patho) physiological 
effect mediated by type I receptors provided that glucocorticods can gain access to 
type I receptors. There seems to be an operational difference between Type I 
receptors in the central nervous system and the periphery. Whereas the 
aldosterone and corticosterone appear to have similar biological effect on blood 
pressure when they bind peripheral Type I receptors, their effects mediated by 
central Type I receptors are opposite ( 185). 
In conclusion, RU 486 has no effect on DOCA-salt model of experimental 
hypertension but significantly increased the hypertension in SHR suggesting that 1) 
RU 486 specifically inhibits glucocorticoid-induced hypertension and 2) it is likely 
that mineralocorticoids are involved in the development and maintenance of 
hypertension in the SHR. 
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Figure 1: Effect of glucocorticoid agonist dexamethasone and the antagonist 
RU 486 treatment on systolic blood pressure (SBP). Each point 
represents mean ± SEM of six male Sprague-Dawley rats. *p<O.05 
compared with control rats. 
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Figure 2: Effect of mineralocorticoid agonist DOCA, and glucocorticoid 
antagonist RU 486 treatment on SBP. Each point represents mean 
± SEM of eight male Sprague-Dawley rats. 
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Figure 3: Effect of gluococorticoid antagonist RU 486 treatment on SBP of 
spontaneously hypertensive rats (SHR). Each point represents mean 
± SEM (n=8). *p<O.05 compared with control rats. 
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Body Weight (gms) 
day 0 
day 8 
day 20 
Saline intake 
(mljday) 
Ur ine volume 
(mI/24h) 
Kidney weig ht (gms) 
Heart weight (gms) 
TABLE I 
Effect of DOCA and DOCA plus RU486 on body weight, water intake, 
urine output and organ weight on Sprague-Dawley rats. 
Control 
305 ± 3 · 6  
280 ± 9 · 0  
309 ± 9 · 7  
21 · 8  ± 2 · 0  
1 4 · 5  ± 1 · 9 
1 · 52 ± · 082 
0 · 95 ± · 037 
DOCA 
307 · 9  ± 4 · 4  
281 ± 1 1 · 9  
295 ± 1 1 · 9  
54 · 25 ± 2 · 8  
1 5 · 5  ± 2 · 27 
1 · 98 ± 0 · 079 
1 · 005 ± 0 · 032 
DOCA + RU486 
292 ± 5 · 4  
278 ± 5 · 6  
308 ± 9 · 1 
66 · 25 ± 3 · 5* 
23 ± 3 · 2* 
1 · 99 ± · 09 
1 · 044 ± · 034 
c.n 0-
TABLE I I  
Effect o f  RU486 treatment on weight,  f luid intake, 
urine volume and organ weights on spontaneously hypertensive rats (SHR) .  
Control R U486 1 mg R U 486 5mg 
Body Weight (gms) 
7 days 1 89 ± 4 · 9  1 93 ± 3 · 8  1 90 · 5  ± 3 · 5  
1 4  days 2 1 3  ± 3 · 9  232 ± 4 · 2  2 1 3  ± 4 · 5  
22 days 232 ± 4 · 1  240 ± 5 · 7  235 ± 3 · 7  
Water intake 
(ml/day) 21 · 80 ± 0 · 87 21 · 30 ± 1 · 09 23 · 48 ± 1 · 3 
Ur ine volume 
(ml/24h) 5 · 07 ± 0 · 42 5 · 1 7 ± 0 · 398 4 · 5  ± 0 · 364 
Liver weight (gms) 8 · 8  ± 0 · 44 8 · 76 ± 0 · 43 9 · 2  ± 0 · 1 8  
Kidney weight (gms) 1 · 56 ± · 039 1 · 78 ± · 01 3  1 ·  7 1  ± · 024 
Heart weight (gms) 0 · 97 ± · 035 0 · 87 ± · 032 0 · 928 ± · 034 
Thymus weight (gms) 0 · 24 ± · 01 4  0 · 1 7 ± · 008 0 · 22 ± · 0075 
'" 
...., 
CHAPTER 2 
The Role of the Mineralocorticoid Antagonist, 
RU 26752 in Adrenocorticosteroid-Induced Hypertension 
Abstract 
The effect of mineralocorticoid antagonist RU 26752 on the development 
and maintenance of hypertension produced by long-term administration of 
mineralocorticoid agonist aldosterone has been investigated. Uninephrectomized, 
saline-drinking male Sprague-Dawley rats were subcutaneously implanted with 
either placebo (control) pellets, 100 J1.g aldosterone pellets, 50 mg RU 26752 
pellets or 100 J1.g aldosterone + 50 mg RU 26752 pellets. Aldosterone treatment 
resulted in an increase in blood pressure to 165 ± 5 mmHg over the control value 
of 105 ± 2 mmHg within 3 weeks of experimental period. RU 26752 given alone 
had no observable hypertensinogenic effect. However, RU 26752 administered 
with aldosterone significantly prevented the hypertension produced by aldosterone 
alone. RU 26752 when given with aldosterone was able to prevent the 
aldosterone-induced increase in saline consumption, increase urine output and 
reduce urinary Na+ excretion. Microscopic examination did not show any 
significant lesions in either heart or kidney of the four groups examined. RU 
26752 (7.5 mg or 15 mg) administered to Sprague-Dawley rats was unable to 
58 
prevent hypertension produced by the administration of dexamethasone. The 
results presented suggest that long-term administration of the 
antimineralocorticoid RU 26752 in vivo to Sprague-Dawley rats prevents the 
aldosterone-induced hypertension and not dexamethasone-induced hypertension. 
59 
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Introduction 
Presently, two steroidal aldosterone antagonists are being used clinically in 
the treatment of mineralocorticoid excess diseases. The widely used 
antimineralocorticoid is spironolactone. Spironolactone was the first competitive 
aldosterone antagonist used as an orally active drug. 
in vitro studies show that spironolactone in ten times higher concentration is 
needed to displace 3H-aldosterone from the receptor binding sites (202). This 
suggests that the relative affinity of spironolactone in vitro compared to 
aldosterone. Studies demonstrate that spironolactone also inhibits aldosterone 
synthesis stimulated by ACTH, potassium or Ang II (223). Although the effect on 
aldosterone synthesis is evident in vitro, the decrease in plasma and urinary 
aldosterone levels during spironolactone treatment is only transient (223). Thus, 
the natriuretic effect of spironolactone in vivo appears to be mainly due to its 
antagonism of the mineralocorticoid receptors in the target tissues. However, 
spironolactone is not specific for the mineralocorticoid receptor. It has affinity for 
the androgen and progesterone receptors as well (202). This has resulted in 
numerous endocrinological side effects with spironolactone treatment. 
Spironolactone inhibits menstruation in rabbits, monkeys (224) as well as in 
women (202) indicating a progestational activity of the drug. It also interferes 
with the secretion and the peripheral action of androgens. Administration of large 
doses of spironolactone causes a significant reduction in the synthesis of 
testesterone (202). This effect may be due to spironolactone inhibiting the 17-
hydroxylase and 17-20-desmolase activities. This antiandrogenic effect of 
spironolactone might explain the impotence and gynecomastia observed in men 
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treated with spironolactone (224). Thus, the therapeutic value particularly during 
long-term treatment with spironolactone is limited. 
The second aldosterone antagonist used clinically is potassium canrenoate 
which has been shown to possess a lower anti androgenic activity in men (225) .  
However, the antimineralocorticoid potency of potassium canrenoate is lower than 
that of spironolactone (202) . In addition, the progestogenic potential of 
canrenone, the active metabolite of potassium canrenoate, is higher than 
spironolactone (227). 
Therefore, both spironolactone and potassium canrenoate are far from 
being the ideal aldosterone antagonists and the search for a more specific 
mineralocorticoid antagonist with reduced adverse side effects has been necessary. 
Several chemical modifications have been made on the spironolactone 
molecule in search of a better mineralocorticoid antagonist with a markedly 
reduced affinity for the androgen and progesterone receptors while the affinity for 
the mineralocorticoid receptor is increased. 
The affinity of 24 spironolactone analogues to the rat renal cytoplasmic 
aldosterone receptor in vitro has been studied by Funder et al. (228). They 
demonstrated a reduction in affinity for aldosterone receptor in analogues with 1) 
unsaturation at CJC7 position in ring B; 2) un saturation of the a-lactone; 3) 
opening of the a-lactone ring. Substitution of the 7-a-thioacetyl group of 
spironolactone by a propyl residue has yielded a compound designated RU 26752. 
This compound is synthesized by scientists at Roussel-Uclaf. RU 26752 has been 
shown to possess increased specificity for the mineralocorticoid receptor over 
spironolactone (229). Interestingly, in vitro studies from this laboratory 
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demonstrated that the kinetics of 3H-RU 26752-mineralocorticoid receptor 
binding, suggested two classes of receptor sites in the rat kidney (230). One class 
is of high affinity, low capacity in the 1-10 nM range followed by another class 
with a low affinity high capacity range in the 10-100 nM 3H-RU 26752. The latter 
class of receptors have little affinity for aldosterone. The increased specificity of 
RU 26752 was confirmed by the observations that there was no binding to other 
serum carriers from organs that are not a target for the mineralocorticoid 
hormones and also by the lack of displacement of 3H-RU 26752 by cold steroids 
(230). However, the correlation between the relative affinity of RU 26752 and its 
in vivo pharmacological activity is not known. Therefore, this study was 
conducted to confirm the in vitro studies demonstrating increased specificity of RU 
26752 to the mineralocorticoid receptor. For the first time, the effect of long­
term in vivo administration of this novel synthetic compound on the development 
and maintenance of aldosterone-induced hypertension in rats was studied. Further 
studies were conducted to show if RU 26752 prevents only mineralocorticoid­
induced hypertension without exhibiting any glucocorticoid agonist or antagonist 
properties by its effect on dexamethasone-induced hypertension. 
Materials and Methods 
For initiating aldosterone-induced hypertension, animals were right 
mononephrectomized under ether anesthesia and maintained on Purina Chow 
and 1 % saline ad libitum. A week after mononephrectomy, a small incision under 
ether anesthesia was made and custom-made pellets containing either placebo 
(n= 6), 100 !log aldosterone (n=6), 50 mg RU 26752 (n=6) or 100 !log aldosterone 
plus 50 mg RU 26752 (n=6) were inserted subcutaneously. Custom pellets were 
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used to deliver the constant dose of steroid agonist, antagonist and combination of 
agonist and antagonist. The pellets were obtained from Innovative Research of 
America (Toledo, OH). These pellets conveniently released the desired drug in 
vivo within three weeks in a controlled dose-dependent manner. 
For initiating dexamethasone-induced hypertension, four groups of rats 
(n= 8) were given 1M injections of either 0.2 ml olive oil/300 gm, 1.5 mg 
dexamethasone/300 gm, 1.5 gm dexamethasone + 7.5 mg RU 26752/300 gm or 1.5 
mg dexamethasone + 15 mg RU 26752/300 gm, dissolved in 0.2 ml olive oil every 
third day for 18 days (total 7 injections). 
Systolic blood pressure (SBP) was measured on days 0, 7, 14 and 21. The 
body weight, water intake and urine output were monitored. The Na+ 
concentration in the urine was measured by flame photometry. At the end of the 
experimental period, the animals were exposed to carbon dioxide and immediately 
killed by cervical dislocation. The organs were removed quickly and weighed. The 
kidney and heart tissues were preserved in formalin and histological preparation 
was done later for morphological examination. Analysis of variance was carried 
out and means were analyzed by Scheffe contrasts for comparison. 
Experiments conducted with the SHR were not successful and due to drug 
and animal constraint, the experiment could not be repeated. 
Results 
First, we determined the optimum dose of aldosterone required to produce 
a significant increase in blood pressure in mononephrectomized, saline drinking 
rats. It was observed that 100 J.Lg aldosterone pellets gave a significant increase 
in blood pressure (162 ± 4 mmHg) over control animals ( 107 ± 2 mmHg) within a 
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three-week period (data not shown). Therefore, 100 J.lg aldosterone pellets were 
used in subsequent experiments. Next, we determined the optimum dose of RU 
26752 needed to antagonize the hypertension produced by the 100 J.lg aldosterone 
pellet (which delivered about 5 J.lg aldosterone/day). Mononephrectomized saline 
drinking rats were subcutaneously inserted with 100 J.lg aldosterone pellet and then 
daily injected with either 500 J.lg, 1 mg or 2.5 mg RU 26752 in 0.2 ml olive oil for 
three weeks. We noted a significant decrease in the blood pressure in the 
aldosterone-treated animals injected with 2.5 mg of RU 26752 along with 100 J.lg 
aldosterone. Results obtained with 50 mg of RU 26752 pellet (which releases 2.5 
mg RU 26752/day) are therefore presented in Figure 4. This figure shows the 
differences among control, aldosterone, RU 26752 and aldosterone plus RU 
26752-treated rats over three weeks. While the blood pressure of 
mononephrectomized, saline-drinking control and RU 26752-treated rats was 
slightly increased, blood pressure was significantly elevated in the aldosterone­
treated (165 ± 5 mmHg) as compared to control rats ( 105 ± 3 mmHg). This 
increase was significantly prevented by simultaneous administration of 
antimineralocorticoid RU 26752 with aldosterone ( 1 12 ± 4 mmHg). 
Data presented in Table III show that there was no significant difference in 
weight gain among the four groups. Saline intake and urinary excretion of water 
were higher during 11 and 18 days in aldosterone-treated rats as compared to 
control rats. On the other hand, RU 26752 and RU 26752 plus aldosterone­
treated animals maintained water intake and urinary output at the level of control 
animals. 
Urinary sodium excretion was found to be significantly reduced in the 
aldosterone-treated animals on day 11 but returned to control level on day 18 
(Table III). No significant changes in urinary Na+ excretion were noted in RU 
26752 or RU 26752 plus aldosterone-treated animals as compared to control 
animals. Microscopic examination of the hearts and kidneys from the four 
experimental groups showed no significant abnormalities. 
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Results presented in Figure 5 demonstrates that dexamethasone treatment 
to Sprague-Dawley rats resulted in a rapid increase in the blood pressure. By day 
18, dexamethasone-treated animals had attained a blood pressure of 158 ± 4 
compared to 118 ± 4 observed for the control (untreated) animals. RU 26752 at 
either 5 times or 10 times the amount of dexamethasone (1 .5 mg) was unable to 
reverse the hypertension produced by dexamethasone during the three-week 
experimental period (Fig. 5). Dexamethasone-treated animals lost significant 
weight during three weeks of steroid administration and RU 26752 has no 
significant effect on reversing the observed weight loss induced by dexamethasone 
(Fig. 6). 
Dexamethasone treatment resulted in increased water consumption, urinary 
output, and a decrease in liver, kidney, heart and thymus wet weight over control 
untreated animals (Table IV). RU 26752 at two different doses given in 
combination with dexamethasone was unable to reverse any of the above effects 
induced by dexamethasone treatment. 
Discussion 
Although DOCA-salt is a well-established model of experimental 
mineralocorticoid hypertension in the rats, we have chosen aldosterone 
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administration combined with high salt intake and reduced renal mass as a model 
for mineralocorticoid-induced hypertension in the present study. We have chosen 
aldosterone-induced hypertension because the majority of clinical 
mineralocorticoid-dependent hypertension is due to an excess of aldosterone and 
not DOC (3). Though hypersecretion of DOC occurs in congenital adrenal 
hyperplasia (CAR), such cases are very rare (9). Moreover, very large doses of 
DOC which is wel1 above physiolgoical levels is required to induce 
mineralocorticoid hypertension in experimental animals. Since this is the first time 
the antimineralocorticoid RU 26752 was being used to antagonize the in vivo 
actions of mineralocorticoids we thought it necessry to use a more potent 
mineralocorticoid, aldosterone which is needed in microgram quantities to induce 
hypertension as compared to milligram quantities of DOCA (174-176). Other 
researchers have used aldosterone infusion to show a dose-dependent change in 
blood pressure of rats (9). Some studies show that the hypertensinogenic potency 
of aldosterone is superior to DOC in the rat as hypertension is produced by the 
administration of aldosterone doses which results in plasma levels no greater than 
that caused by stress (23 1). 
In this study, we present evidence suggesting that aldosterone-induced 
hypertension in uninephrectomized salt-drinking Sprague-Dawley rats can be 
prevented by the simutaneous administration of the antimineralocorticoid RU 
26752. While an effective dose ratio of 1 Jl.g aldosterone: 26.8 mg spironolactone 
has been reported in rats (232), we have shown in this study a ratio of I Jl.g 
aldosterone; 0.5 mg RU 26752 to be effective in preventing aldosterone-induced 
hypertension in rats. RU 26752 unlike the antialdosterone potassium prorenoate 
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which had a higher affinity for the mineralocorticoid receptor than spironolactone 
in vitro but was shown by Funder et al. to have a very low affinity for the receptor 
in vivo (228). This confirms the in vitro studies demonstrating that RU 26752 
binds the mineralo�orticoid receptor with greater affinity and specificity than that 
of spironolactone (229) . 
However, a rather high concentration of RU 26752 is still neeeded to 
antagonize the hypertensive effect of aldosterone in vivo. The ratio of aldosterone 
to RU 26752 is 1 :500. In this regard, it is interesting to note that Lazar and 
Agarawal (230) reported a distinct anti-mineralocorticoid binding site in rat kidney 
which was physicochemically different from the well-characterized 
mineralocorticoid receptor in various target tissues. They showed evidence for a 
mineralocorticoid receptor with low affinity, high capacity that binds antagonist but 
not agonist. Therefore, it is likely that in vivo, a larger amount of RU 26752 is 
needed to exert its effect on high affinity aldosterone binding sites. Alternatively, 
it is possible that RU 26752 may be converted in vivo to a metabolite(s) with 
reduced biological activity therefore larger amounts are required. 
Aldosterone when given alone significantly increased saline consumption 
and urinary output with low Na+ excretion compared to control animals. 
Increased saline intake and subsequent polyuria characteristic of mineralocorticoid 
hypertension have been shown in several studies (179,221,222) . In all these 
studies the A V3V region of the brain which regulates thirst, sodium balance and 
blood pressure has been implicated. Destruction of the A V3V region has been 
shown to reverse hypertension caused by mineralocorticoids and high salt intake 
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(179,221). However, Gomez-Sanchez has suggested that the prevention of 
DOCA-salt hypertension by the lesioning of A V3V region may be due to 
destruction of specific pressor functions and not so much as the destruction of 
thirst and salt appetite centers (233). On the other hand, many studies have 
demonstrated that mineralocorticoid hypertension does not develop if sodium 
intake is restricted ( 120, 121, 124) and therefore the salt appetite center is 
important in this model of experimental hypertension. RU 26752 administered 
together with aldosterone reversed the increase in saline consumption and Na+ 
retention induced by aldosterone. RU 26752 was devoid of any pressure effect 
when given alone and had no effect on either saline consumption, diuresis or on 
Na+ excretion. Thus, RU 26752 seems to have no mineralocorticoid agonist 
properties in vivo. Also RU 26752 was observed to have no deleterious effects 
when given alone or together with aldosterone on either kidney or heart as noted 
under microscopic examination. Morphological examination of the heart and 
kidney tissues is relevant in assessing the toxic side effects of these steroid 
hormone antagonists as antihypertensive drugs. It is a well-established clinical fact 
that a sustained and signficant reduction in arterial pressure is followed by the 
development of heart failure or myocardial infarction in hypertensive patients 
(234). In addition, experimental myocardial infarction in SHR was associated with 
prolonged reduction in blood pressure (235). The side effect from most 
antihypertensive drugs is renal failure and the histology is that of acute interstitial 
nephritis (236). 
It is important to know whether RU 26752 is specific for mineralocorticoid­
induced hypertension or it also has glucocorticoid antagonist properties. Our 
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results suggest that RU 26752 administered at 7.5 mg (5x the dose of dex) or even 
at 15 mg (lOx dose of dex comparable to dose of RU 486 by ratios) is devoid of 
any glucocorticoid agonist or antagonist properties as it had no effect on 
glucocorticoid-induced hypertension. Thus RU 26752 seems to possess pure 
antimineralocorticoid properties in terms of its hypertensive effects in steroid­
induced hypertension. 
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Figure 4: Effect of mineralocorticoid agonist aldosterone and antagonist RU 
26752 treatment on SBP. Each point represents the mean ± SEM 
of two separate experiments using Sprague-Dawley rats (n=6) in 
each experiment. *p<0.05 compared with control rats. 
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Figure 5: Effect of mineralocorticoid antagonist RU 26752 on dexamethasone­
induced hypertension. Each point represents the mean ± SEM using 
Sprague-Dawley rats (n=8) in each group. *p<O.05 compared with 
control rats. 
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Figure 6: Body weight in dexamethasone and dexamethasone plus RU 26752 
treated rats. Each point represents the mean ± SEM using Sprague­
Dawley rats in each group. *Significant differences from 
corresponding value in control untreated animals (P< .05). 
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Tab l e  I I I  
E f fe c t  o f  m ineral o c o r t i c o i d  agon i s t  aldos te rone and antagoni s t  RU 2 6 7 5 2  
t r e a tment o n  body we i gh t , s a l ine intake , urine output and excre t i on o f  s o d 5.um . 
Body We i gh t  ( g ) 
Contro l 
Aldo s te rone 
RU/2 6 5 7 2  
RU/ 2 6 7 5 2  + A l do s te rone 
S a l ine Intake ( ml/24h)  
Contro l 
Aldo s t e rone 
RU/2 6 7 5 2  
RU/2 6 7 5 2  + A l do s te rone 
Urine output ( m l/24h ) 
Contro l 
Aldo s t e rone 
RU/ 2 6 7 5 2  
RU/ 2 6 7 5 2  + A l d o s t e rone 
Sod ium ( me q/24h ) 
Control 
A l do s t e r one 
RU/ 2 6 7 5 2  . 
RU/2 6 7 5 2  + A l do s te rone 
0 
2 2 5±6 
2 3 4±S 
2 2 S±S 
242±10 
2 S±2 . 1  
2 9±2 . 6  
3 1 . 2±3 . 1  
2 6 . 4±2 . 4  
1 6 . 8±1 . 6  
1 7 . 6±2 . 1  
1 5 . 2±1 . 4 
1 7 . 4±2 . 1  
2 . 4±O . 3  
2 . 6±O . 3  
2 . 6±O . 1  
2 . 4±O . 3  
Values exp r e s s e d  are mean ± S EM ( n�6 ) . 
Days a f t e r  trea tment 
1 1  
24 S±7 
2 5 2±6 
2 6 1±7 
2 7 4±9 
3 0 . 2±2 . 6  
* 5 2 . 2±1 . S 
3 5 . 2±1 . 6  
3 S . S±2 . 1  
1 4 . 3±1 . 2 
* 2 4 . S±3 . 2  
l S . 2±1 . 6  
1 9 . 3±1 . 4 
2 . S±O . 2  
* 1 . 7±O . 1 
2 . 4±O . 3  
2 . 2±O . 2 
I S  
2 S 2±4 
3 0 4±4 
2 S 0±5 
3 0 6±7 
3 S . 6±3 . 2  
" 5 1 .  2±2 . 8 
3 6 . 1±3 . 1  
3 9 . 2±1 . S 
1 7 . 1±1 . 5  
" 3 1 .  2±4 . 1  
1 7 . 6±1 . S  
1 9 . 5±1 . 3  
2 . 4±O . 2  
2 . 1±O . 2  
2 . 7±O . 2  
2 . 4±O . 1  
* S i gn i f i cant d i ffe rence from corresponding value in control  untreated anima l s  
( P<O . 0 5 )  
7 7  
TABLE IV 
Effe c t  of gluc o c o r i t o c i d  agoni s t ,  dexame thasone and mineralo c o r t i c o i d  antagon i s t  
RU 2 6 7 5 2  t r e a tment o n  fluid intake , urine vo lume and o r gan we i gh t s . 
control Dex 
1 . 5mg 
Wa t e r  I n t ake 
( m l/day ) 3 2 . 8±0 . 8 2 '40 . 7 5±1 . 2 6 
U r i ne output 
( m l / 2 4h )  1 1 . 8 5±0 . 6 4  ' 2 1±0 . 8  
Liver we i gh t  1 4 . 16±0 . 6 7 ' l O . 5±0 . 2 5 
K i dney we i gh t  3 . 14± . 9 6  ' 2 . 3 5± . 01, 
H e a r t  we i gh t  1 . 2 9± . 0 5 'O . 9 8± . 0 5 
Thymus we i gh t  0 . 4 9± . 0 2 8  'O . 2± . 0 2 4  
Adrenal we i gh t  . 0 7 l± . 0 0 6  . 0 3 7± . 0 0 2  
Value s expre s s e d  are m e a n  ± S EM ( n�8 ) 
*P<0 . 0 5 c ompared w i th contro l . 
RU2 6 7 5 2  
7 . 5mg 
+ 
Dex 
1 . 5  mg 
'43±1 . 6 
' 1 7±3 8 
' 1 1 . 1 6±0 . 5 
' 2 . 5± .  0 8  
' 1 . 005± . 04 
'O . 1 9 8± . 0 1 6  
'0 . 04± . 004 
RU2 6 7 5 2  
1 5  mg 
+ 
Dex 
1 . 5  mg 
'40 . 7 5±1 . 2 
' 2 1 . 7±0 . 6  
' 1 1 . 04±0 . 2 3  
'2 . 3 5± . 0 8 
'0 . 9 4 5± . 0 2 6  
'0 . 2 5 4± .  0 2  
'0 . 0 3 6± .  0 0 2 4  
CHAPTER 3 
The Role of the Novel Antimineralocorticoid, Mespirenone, on 
Adrenocorticosteroid-Induced Hypertension 
Abstract 
The effects of the aldosterone antagonist mespirenone on the development 
and maintenance of hypertension in three different experimental models of 
hypertension were studied. Uninephrectomized saline-drinking male Sprague­
Dawley rats injected i.m. with either 0.2 ml olive oil (control), 50 J.Lg aldosterone, 1 
mg mespirenone, 50 J.Lg aldosterone plus 500 J.Lg mespirenone or 50 J.Lg aldosterone 
plus 1 mg mespirenone, each dissolved in 0.2 ml olive oil. Administration of 
aldosterone alone significantly increased the systolic blood pressure (SBP) from a 
control value of 114 ± 3.6 to 162 ± 4 by the end of the three-week experimental 
period. Mespirenone given alone had no effect on SBP. However, mespirenone 
given in combination with aldosterone reversed the hypertension caused by 
aldosterone in a dose-dependent manner. Saline consumption and urinary output 
were slightly increased in aldosterone-treated rats as compared with the other 
groups but the body weight and organ weights were comparable in all groups. 
Also microscopic examination of kidney and heart showed no abnormalities. On 
the other hand mespirenone was unable to prevent the dexamethasone-induced 
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hypertension. Instead, the blood pressure was slightly increased (169 ± 3.3) when 
mespirenone was administered simultaneously with dexamethasone as compared 
to dexamethasone alone (142 ± 3.0). Interestingly, mespirenone potentiated 
dexamethasone-induced thymic involution and was unable to reverse the body 
weight loss resulting from dexamethasone treatment. However, the kidney and 
heart weights were not affected by mespirenone treatment. SHR animals were 
given two different doses of mespirenone. At the end of the three-week 
experimental period, rats injected with 2.5 mg mespirenone showed a reduction in 
SBP (198.3 ± 3.6) compared to control SHR given only olive oil (215.2 ± 2.8) and 
rats injected with 5 mg mespirenone demonstrated a further reduction in the SBP 
( 190.0 ± 2.6). However, statistical analysis of the data showed no significant 
difference between SHR treated with mespirenone and control SHR. These 
results suggest that the in vivo administration of mespirenone to rats (i) effectively 
prevents the aldosterone-induced hypertension and (ii) had no effect on 
dexamethasone-induced hypertension. (iii) As compared to glucocorticoids, it is 
suspected that mineralocorticoids may be more involved in the development of 
hypertension in the SHR. 
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Introduction 
Though different chemical substitutions have been made on the 
spironolactone molecule in the hope of decreasing its antiandrogenic and 
progestogenic activities while at the same time increasing its anti-aldosterone 
potency, no new steroidal anti-mineralocorticoid has been introduced into the 
therapy of aldosterone-dependent diseases. Studies have shown that the 
introduction of a 1,2 double bond into the spironolactone molecule leads to a 
reduction in the affinity for the androgen and progesterone receptors without 
changing the antimineralocorticoid potency in vitro (237). Additional modifications 
introducing a 15, 16-methylene moiety significantly increased the 
antimineralocorticoid potency (238). Such a compound with chemical 
modifications of a 1,2 double bond and 158, 168 methylene ring on the 
spironolactone molecule has been synthesized by researchers at Schering and it is 
known as mespirenone (72-acetylthio-158, 168-methylene-3-oxo-17 a-pregna-l,4-
diene-21, 17-carbolactone). In animal studies mespirenone exhibited a three-times 
greater antiandosterone potency and less than 10% of the anti androgenic activity 
of spironolactone (238). In these studies, the antimineralocorticoid effect of 
mespirenone was assessed by its ability to reverse the renal action of aldosterone 
which is the sodium retaining and potassium diuretic effect. 
In humans, Seibert et al. reported that the antimineralocorticoid potency of 
mespirenone following oral administration was about six times higher than 
spironolactone (239). From a therapeutic point of view, an increase in 
antimineralocorticoid potency of a new aldosterone antagonist by itself is 
desirable. Moreover, in vivo studies in humans showed no progestogenic activity 
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of mespirenone even at pharmacological doses (240). Thus, rnespirenone 
appears to be the aldosterone antagonist that researchers have been searching for. 
However, up until now the in vivo studies involving mespirenone have focused on 
its natriuretic property and its endocrinological profile. Since one of the most 
common complications of excess mineralocorticoids is hypertension, it is necessary 
to study the in vivo effect of mespirenone on hypertension in assessing its anti­
mineralocorticoid potency. Therefore, for the first time, a long-term study of the 
antihypertensive effect of rnespirenone on three different experimental models of 
steroid-induced hypertension was conducted. 
Materials and Methods 
Three experiments were conducted to study the role of mespirenone in 
steroid-induced hypertension. To initiate aldosterone-salt-induced hypertension, 
Sprague-Dawley rats were uninephrectomized under ether anesthesia and given 
0.9% saline. One week later, the rats were divided into five groups each 
containing six rats (n=6).  They were injected every other day over a period of 18 
days. Group I was given 0.2 rnl olive oil (control), Group II received 50 J.Lg 
aldosterone/300g, Group III was treated with 1 mg mespirenone/300g, Group IV 
with a combination of 50 J.Lg aldosterone and 500 J.Lg mespirenone/300g (10 times 
the dose of aldosterone), and Group V with a combination of 50 J.Lg aldosterone 
and 1 mg mespirenone/300 (20 times the dose of aldosterone). Aldosterone and 
mespirenone doses for these experiments were chosen based on dose-response 
studies done previously in this laboratory (unpublished data). 
To induce dexamethasone hypertension, Sprague-Dawley rats were divided 
into four groups with eight rats in each group (n=8). Group I was injected with 
0.2 ml olive oi1/300g, Group II with 1.5 mg dexamethasone/300g, Group III with 
both 1 .5 mg dexamethasone and 15 mg mespirenone/300g (10 times the dose of 
dexamethasone), and Group IV received 1.5 mg dexamethasone and 30 mg 
mespirenone/300 (20 times the dose of dexamethasone). 
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SHR animals were divided into three groups with eight rats in each (n=8).  
Group I was injected with the vehicle 0 .2 ml olive oil, Group II with 2 mg 
mespirenone/150g and Group III 5 mg mespirenone/150g dissolved in 0.2 ml olive 
oil. 
Baseline systolic blood pressure (SBP) was measured before steroid 
administration and then once a week thereafter. An average of six to eight blood 
pressure measurements within 5 mmHg of each other was used as the 
representative SBP for each animal. The mean body weight was taken over 6 to 8 
readings and this represented the body weight of each rat. Fluid consumption and 
urinary output over a 24-hour period were collected on two consecutive days each 
week. At the end of each experiment, the rats were anesthetized with carbon 
dioxide and quickly killed by cervical dislocation. The heart, kidney, liver and 
thymus were removed and weighed. Histological preparations were done with the 
heart and kidney tissues for morphological examinations of any possible lesions 
due to hormone antagonists treatment. Data were analyzed by the two-way 
analysis of variance followed by the Scheffe test for multiple comparisons. 
Results 
Results presented in Figure 7 show a very rapid increase in the blood 
pressure of aldosterone-treated rats over control rats within a week of steroid 
administration and remained throughout the experimental period. This increase in 
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the blood pressure was completely prevented by the mineralocorticoid antagonist 
mespirenone given simultaneously with aldosterone. Five hundred (500) J.Lg of 
mespirenone given together with 50 J.Lg of aldosterone reduced the SBP from 162 
± 3.4 (aldosterone-treated value) to 126 ± 3.4 and 1 mg mespirenone plus 50 J.Lg 
reduced it to 116 ± 1.9 which was similar to the control value (114 ± 3.6). 
Data presented in Table V indicate no significant change in body weight in 
all five groups. Although saline consumption was higher in the aldosterone­
treated rats, this was followed by a correspondingly higher urinary output. 
However, the simultaneous administration of mespirenone with aldosterone 
maintained saline intake and urinary output at the level of the control animals. 
There was no significant difference in the organ weights among the groups (Table 
VI) . Microscopic examination of the kidney and heart showed no significant 
lesions. Microscopic changes were limited to minimal focal myocyte fuchsinophilia 
of the myocardium which is considered to be insignificant (Data not shown). 
Results shown in Figure 8 demonstrate a rapid and significant increase in 
blood pressure within a week of dexamethasone treatment which continued until 
the end of the experiment. Mespirenone at two different doses given in 
combination with dexamethasone was unable to prevent the hypertension induced 
by dexamethasone treatment. Surprisingly, the blood pressure of rats treated with 
a combination of dexamethasone and mespirenone (160 ± 3.6; 169 ± 3.5) was 
higher than rats treated with dexamethasone alone (142 ± 2.5) but the difference 
was not statistically significant. Thus, mespirenone seemed to have potentiated 
dexamethasone-induced hypertension. As observed in Table VII a three-week 
dexamethasone treatment significantly decreased the body weight (289.5 ± 9.0) as 
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compared to controls (372.6 ± 7.9) and mespirenone was unable to prevent this 
weight loss (291.5 ± 8.0; 300 ± 13.6). Interestingly, simultaneous administration of 
mespirenone and dexamethasone resulted in complete involution of the thymus 
while dexamethasone administered alone caused a partial involution of the thymus 
(Table VII) . However, heart and kidney weights were not affected by the 
treatment and no abnormalities were found in the hearts and kidneys of the 
treated groups under microscopic examination. Water intake and urinary output 
were comparable in all groups (Table VIII) . 
Data presented in Figure 8 demonstrate that mespirenone does not prevent 
hypertension developed by SHR. Although the SBP of the rats treated with 
mespirenone at two different doses (198 ± 3.6; 190.5 ± 2.6) was lower compared 
to control SHR (215.2 ± 2.8), the difference was not statistically significant. There 
was no significant change in body weight, water intake, urinary output and organ 
weights between control SHR and mespirenone-treated SHR animals (Table VII) . 
Discussion 
The results obtained show that aldosterone administered to 
mononephrectomized saline-drinking rats leads to the development of 
hypertension. This hypertension can be prevented by the simultaneous 
administration of the potent mineralocorticoid antagonist, mespirenone with 
aldosterone. To our knowledge, this is the first study to look at the 
antihypertensive effect of long-term treatment with mespirenone combined with 
aldosterone. The potency of this aldosterone antagonist can be appreciated when 
this study is compared with studies involving other mineralocorticoid antagonists. 
Results in the previous study show that the newly synthesized 
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antimineralocorticoid RU 26752 by Roussel Uelaf, prevents aldosterone-induced 
hypertension in Sprague-Dawley rats (241). However, very high doses of RU 
26752 were needed to effectively prevent aldosterone-induced hypertension as 
compared to mespirenone. To antagonize aldosterone-induced hypertension, 
studies show that an optimum dose of RU 26752 five hundred times more than 
the dose of aldosterone which caused an increase in the blood pressure was 
needed, whereas only ten times the dose of the same amount of aldosterone was 
needed for mespirenone. Studies involving spironolactone show that even a 
higher dose than RU 26752 was employed to antagonize mineralocorticoid actions 
in vivo (232). In rats, a dose of spironolactone as high as 26.8 mglkglhr is 
administered to counteract aldosterone action in vivo (232). In patients with 
mineralocorticoid-excess diseases, a dose of 200-400 mg/day of spironolactone is 
given (193). Therefore, the reduction of the therapeutic dose of mespirenone will 
not only be economically advantageous but will offer less chance of side effects. 
Preliminary studies have been done by other researchers to evaluate the 
natriuretic effect of mespirenone and observed a three-times higher potency in 
rats (238) and a six-times higher potency in humans (239) as an 
antimineralocorticoid than spironolactone. Unlike spironolactone, mespirenone 
has been shown to have no progestational activity after two weeks of treatment in 
humans (239) and a markedly reduced antiandrogenic activity (238). Thus, the 
potency of mespirenone as a mineralocorticoid antagonist with reduced 
endocrinological side effects is well established. However, the possibility of 
mespirenone possessing some weak mineralocorticoid agonist activity has not been 
investigated until now. It is well known that steroid antagonists may also possess 
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some steroid agonist properties and are known as suboptimal antagonists (203). 
According to these results, rats given mespirenone alone showed a slight increase 
in the blood pressure over control rats. This is consistent with other steroid 
antagonists such as RU 486 which was shown by a study in our lab to possess 
some weak glucocorticoid agonist properties in the early phase of administration 
(5). However, since the increase in blood pressure of the rats treated with 
mespirenone alone was not statistically significant, this slight elevation might be 
due to variabilities in that group and not due to mespirenone treatment. 
Surprisingly, the simultaneous administration of mespirenone and 
dexamethasone caused a complete involution of the thymus. The reason for this 
observation, (mespirenone potentiating dexamethasone-induced thymic involution) 
was unexpected and seems to indicate that mespirenone may have some 
glucocorticoid agonist activity since glucocorticoid-induced thymic involution is 
known to be a Type II-mediated mechanism. But this was proved not to be the 
case as results from another experiment in our lab showed that glucocorticoid 
receptors were not down regulated by mespirenone. Thymus weight was not 
affected by mespirenone treatment in the other groups and microscopic 
examination of the kidney and heart tissues showed no abnormal lesions due to 
mespirenone treatment. 
Thus, mespirenone is a novel mineralocorticoid antagonist which might 
offer clinical advantages over spironolactone in the treatment of mineralocorticoid 
exces diseases such as mineralocorticoid-induced hypertension with far less 
deleterious endocrinological side effects. 
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Figure 7: Effect of the mineralocorticoid agonist, aldosterone and 
mineralocorticoid antagonist, mespirenone, treatment on SBP of 
Sprague-Dawley rats. Each point represents the mean ± *P<O.05 
compared with control rats. 
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Figure 8: Effect of glucocortcoid agonist, dexamethasone, and the 
mineralocorticoid antagonist, mespirenone, treatment on SBP. Each 
point represents mean ± SEM of eight male Sprague-Dawley rats. 
*P<O.OS compared with controls. 
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Figure 9: Effect of mespirenone treatment on systolic blood pressure of 
spontaneously hypertensive rats (SHR) . Each point represents 
means ± SEM of eight rats. 
0
 
�
 
Ul
 
SY
ST
OL
IC
 B
LO
OD
 P
RE
SS
UR
E 
N
 
N
 
N
 
N
 
o
 
N
 
�
 
�
 
�
 
0
 
N
 
�
 
�
 
0
0
0
 0
 
0
 
0
 
0
 
0
 
0
 
o
 +-
--'---'---'---'---1H'{-O:t-
--'----'-----' 
U1
 
O}
O
 
0
 
U1
 
0
[>
 
0
 
N
 
0
 
N
 
U1
 
0
 
� <t> en 01 3 (J)
 
92
 
::!
! 
G>
 
C
 
::rJ
 
m
 
CD
 
[> 
0
 
� 
0
 
<t> 
0 
en 
::l. 
�
 
£ 
"'
. 
<.n 3 (J)
 
TAB L E  V 
Body we i g h t , s a l i n e c o n s umpt i on and  u r i n e  o u t p u t  i n  r a t s  treated w i t h  a l d o s t e r o n e  and  a l d o s t e r o n e  p l u s  
m e s p i r e n o n e .  
C o n t r o l  A l d o  Me s o  Al d o  + 1 0  x M e s o  Al d o  + 2 0  x M e s o  
Body we i g h t  ( gm s ) 
d ay 0 289 ± 5 . 6  284  ± 4 . 9  2 7 3  ± 4 . 7  2 8 1  ± 2 . 5  2 8 2  ± 3 . 9  
d ay 7 3 4 3  ± 7 . 8  3 0 3  ± 1 3 . 7  2 9 9  ± 8 . 8  3 3 4  ± 5 . 4  3 0 8  ± 9 . 4  
d ay 1 4  3 4 1  ± 3 . 5  3 2 2  ± 5 . 2  3 2 7  ± 2 . 2  369  ± 4 . 2  3 1 4  ± 1 0 . 0  
d ay 2 1  4 0 5  ± 6 . 9  388 ± 5 . 9  3 8 0  ± 7 . 2  3 1 7  ± 4 . 5  3 6 2  ± 9 . 5  
U r i n e  o u t  p u t  
( m l / 2 4 h r )  2 5  ± 1 ·  8 * 3 4  ± 1 ·  4 24 ± 2 · 0 5 28 · 0  ± 2 · 4  2 3 · 0  ± 3 · 3 
S a l i n e c o n s umpt i o n 
( m l / 2 4 h r )  3 6 · 4 1 ± 1 · 6 * 4 5 · 9  ± 2 · 4  48 · 3  ± 3 · 4  4 2 · 6  ± 2 · 1  4 0 · 3  ± 3 · 1  
<D '" 
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TABLE V I  
E f fe c t  o f  glucoc o r t i c o i d  agoni s t  I dexame thas one and mineral oco r t i c o i d  
antagoni s t ,  me s p i renone treatment on body we i gh t  a n d  o r gan we i gh t s . 
Trea tment Grou�s 
Contro l Dex Dex Dex 
+ + 
( l Smg M S P )  30mg MSP 
Body We i gh t  ( gm )  
D a y  0 3 1 6 · 8  ± 4 · 5  3 34 · 8  ± 6 · 3  3 3 0 · 3  ± 3 · 9  3 3 0 · 6  ± 3 · 3  
Day 347 · 5  ± 3 · 9  2 9 9 · 6  ± 6 · 7  3 0 3 · 2  ± 6 · 5  2 9 0 · 5 ± 9 · 0  
Day 1 7  3 7 2 · 6  ± 7 · 9  2 8 9 · 5  ± 9 · 0* 2 9 1 · 5 ± 8 · 0" 3 0 0  ± 1 3 · 6** 
Wa t e r  intake 
( ml/24hr)  3 9 . 5  ± 5 . 1  4 1 . 5 ± 4 . 6  3 7 . 4  ± 3 . 8  4 2 . 0  ± 2 . 4  
Urine volume 
(ml/24h r )  1 5 . 6  ± 2 . 6  1 3 . 3  ± 2 . 3  1 5 . 8  ± 2 . 1  1 5 . 5  ± 1 . 7  
Thymus mg 3 /,Omg ± 5 0  8 7  ± 2 0  
Hea r t , mg 1 , 1 8 0  ± 8 0  1 , 000 ± 3 0  1 , 0 5 0  ± 3 0  1 , 01, 0  ± 4 0  
K i dney , m g  2 , 9 40 ± 2 5 0  2 , 8 00  ± 1 1 0  2 , 6 7 0  ± 1 0 0  2 , 9 8 0  ± 1 1 0  
Table VII 
Effect of Mespirenone Treatment on Body Weight, Water Intake, 
Urine Output and Organ Weight of Spontaneously Hypertensive rat (SHR) 
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Control Mespirenone Mespirenone 
Body Weight (g) (2.5 mg) (5 mg) 
Day 7 337 ± 4.3 336 ± 2.5 339 ± 6.2 
Day 14 343 ± 5.7 337 ± 4.1 334 ± 8.5 
Day 21 361 ± 4.3 351 ± 3.7 345 ± 7.5 
Saline Intake 
(ml/day) 28.3 ± 2. 1 23.0 ± 1.8 32. 1 ± 3.2 
Liver weight (g) 13.5 ± 0.4 14.3 ± 0.2 15.1 ± 1 . 1  
Kidney weight (g) 2.8 ± 0.07 3.0 ± 0.04 3.1 ± . 17 
Heart weight (g) 1.5 ± 0.04 1.5 ± 0.02 1.5 ± 0.12 
CONCLUSION 
From the results presented in this study, RU 486 seems to be a potent 
glucorticoid antagonist without any effect on mineralocorticoid hypertension. 
Thus, RU 486 may have potential clinical use in the treatment of glucocorticoid­
induced hypertension, the most common complication associated with 
glucocorticod excess diseases such as Cushing's Syndrome. 
Although the mineralocorticoid antagonist spironolactone, is clinically used 
in the treatment of mineralocorticoid excess diseases, it is limited by numerous 
adverse endocrinological side effects. Accoridng to the results presented here, 
mespirenone appears to be a better substitute for spironolactone than RU 26752 
in the treatment of mineralocorticoid excess diseases. Not only was a far less 
amount needed to antagonize the in vivo actions of aldosterone but also, 
mespirenone has been shown by others to have negligible side effects associated 
with spironolactone. 
This work has established these three novel steroid hormone antagonists as 
potent and specific in vivo. Apart from their potential therapeutic use as 
discussed above, steroid hormone antagonists can be used as tools to probe the 
molecular mechanism of action of steroid hormones about which little is known. 
At this point, it is known that the steroid hormones exert their biological effects by 
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regulating gene expression in the cells of the target tissues. Due to the recent 
availability of cDNA for both the glucocorticoid and mineralocorticoid receptors, 
work has begun in our lab to measure the glucocorticoid receptor and 
mineralocroticoid receptor expression during steroid-induced hypertension and 
during the inhibition of hypertension by these antagonists. This is consistent with 
my objective to explore the molecular mechanism by which steroid hormones 
induce hypertension as more cDNA probes of other steroid-hormone target genes 
become available in the future. 
APPENDIX 
APPENDIX A 
Table VIII 
Effect of the Mineralocorticoid Agonist, DOCA, and the Glucocorticoid 
Antagonist, RU 486, on Systolic Blood Pressure 
Week of Treatment 
Treatment Groups First Second Third 
Control 1 19.0 ± 3.6 127.5 ± 3.5 1 19.3 ± 4. 1 
1 mg DOCA 120.5 ± 3.6 170 ± 2.8 173.6 ± 1.6 
1 mg DOCA + 
10 mg RU 486 121.7 ± 2.4 173.6 ± 1.6 152 ± 3.6 
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APPENDIX B 
Table IX 
Effect of the Glucocorticoid Antagonist, RU 486 Treatment 
on the Systolic Blood Pressure of Spontaneously Hypertensive Rats (SHR) 
Week of Treatment 
Treatment Groups First 
Control 145 ± 2. 1 
1 mg RU 486 140.6 ± 1.4 
5 mg RU 486 145.6 ± 2.4 
Values expressed are mean ± SEM (n=8) 
*(p<0.05) compared with control. 
Second 
147.5 ± 1.7 
155 ± 2.9 
160.9 ± 3.1 
Third 
150 ± 1 .8 
160 ± 2.5 
172.5 ± 2.5 
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APPENDIX C 
Table X 
Effect of the M i neralocorticoid Agonist Aldosterone and the 
Mineralocorticoid Antagonist ,  Mespirenone Treatment on Systol ic Blood Pressure 
Treatment Groups 0 First 
Control 1 09.2 ± 2.4 1 1 0.3 ± 1 . 9  
Aldosterone (Al d o )  l O S . 7  ± 3 . 1 * 1 45 ± 2.6 
Mespirenone (Mes) 1 1 0.0 ± 2.7 1 24.7 ± 4.2  
Ald o  + 1 0  Mes 109.0 ± 1 . 9  1 30. 1 ± 4 . 0  
Aldo + 20 Mes 1 0S.2 ± 3.3 1 1 S.3 ± 1 . 9  
Values expressed as mean ± S E M  ( n = 6) .  
*(p < 0.05) compared to control untreated animals .  
Second 
1 1 4 .2  ± 3 .6  
* 1 6 1 . 6  ± 5 .2  
1 20.0 ± 3 . 3  
125 .0  ± 2 . 6  
1 1 5 . 0  ± 1 . 6  
Third 
1 1 5 ± 2.6 
* 1 62.5 ± 4.S 
1 1 4.0 ± 3 . 9  
1 26.6 ± 3 . 4  
1 10.7 ± 1 . 9  
I-' o o 
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APPENDIX D 
Table XI 
Effect of the Glucocorticoid Agonist, Dexamethasone, and the 
Mineralocorticoid Agonist, RU 26752 Treatment on Systolic Blood Pressure 
Week of Treatment 
Treatment Groups 0 First 
Control 1 15.8 ± 3.6 1 16.3 ± 4.2 
Dexamethasone (Dex) 1 16.0 ± 2.8 * 153.1 ± 2.6 
Dex + RU 26752 (7.5 mg) 1 16.8 ± 2.9 * 146.3 ± 2.4 
Dex + RU 26752 (15 mg) 1 15.6 ± 2.5 * 154.4 ± 2.9 
Values expressed are mean ± SEM (n=8) 
*(P< 0.05) compared to control untreated animals. 
Second 
1 18.8 ± 4.3 
* 158.2 ± 4.2 
* 162.5 ± 3.6 
* 15 1 .9 ± 2.9 
APPENDIX E 
Table XII 
Effect o f  the M i neralocorticoid Agonist Aldosterone and the 
Mineralocorticoid Antagonist ,  Mespirenone Treatment o n  Systol ic Blood Pressure 
Treatment G roups 0 First 
Control 1 09.2 ± 2.4 1 10 .3  ± 1 . 9  
Aldosterone (Aldo) lOS .7  ± 3 . 1  * 1 45 ± 2 . 6  
Mespirenone (Mes) 1 1 0 .0 ± 2.7 1 24 . 7  ± 4 . 2  
Aldo + 1 0  M e s  1 09.0 ± 1 . 9  1 3 0. 1 ± 4.0  
Aldo + 20 Mes l OS.2 ± 3 . 3  l l S .3  ± 1 . 9  
Values expressed as m e a n  ± SEM ( n = 6) .  
* (p < 0.05)  compared t o  control untreated animals .  
Second 
1 1 4.2 ± 3.6 
* 1 6 1 . 6  ± 5 . 2  
1 20.0 ± 3 . 3  
1 25 . 0  ± 2 . 6  
1 1 5 . 0  ± 1 . 6  
Third 
1 1 5 ± 2.6 
* 1 62.5 ± 4.S 
1 1 4 .0  ± 3.9 
1 26 .6  ± 3 . 4  
1 1 0 .7  ± 1 . 9  
f-' o N 
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APPENDIX F 
Table XIII 
Effect of Glucocorticoid Agonist, Dexamethasone, and the Mineralocorticoid 
Antagonist, Mespirenone (Mes), Treatment on Systolic Blood Pressure 
Week of Treatment 
Treatment Groups 0 First 
Control 1 10 ± 2.1 1 15.0 ± 3.2 
Dexamethasone (Dex) 1 10.9 ± 3.6 * 146.0 ± 4.2 
Dex + Mes (15 mg) 1 1 1 .8 ± 4.2 * 157.0 ± 3.2 
Dex + Mes (30 mg) 1 1 1.0 ± 3.0 * 153.2 ± 2.9 
Values expressed are mean ± SEM (n=8).  
* (P< 0.05) compared to control untreated animals. 
Second 
1 17.0 ± 3.3 
* 142. 1 ± 2.5 
*160.2 ± 3.6 
* 169.0 ± 3.5 
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APPENDIX G 
Table XIV 
Effect of the Mineralocorticoid Antagonist, Mespirenone, 
Treatment on Systolic Blood Pressure of Spontaneously Hypertensive Rats (SHR) 
Week of Treatment 
Treatment Groups o First Second 
Control 205.0 ± 3.5 210.1 ± 3.0 215.2 ± 2.8 
Mespirenone (2.5 mg) 196.2 ± 1.9 200.0 ± 2.2 198.3 ± 3.6 
Mespirenone (5 mg) 195.0 ± 2.8 197.2 ± 3.8 190.0 ± 2.6 
Values expressed are mean ± SEM (n=8).  
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